<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199185</article-id><article-id pub-id-type="doi">10.1101/2024.09.30.613582</article-id><article-id pub-id-type="archive">PPR918497</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Typhi Mykrobe: fast and accurate lineage identification and antimicrobial resistance genotyping directly from sequence reads for the typhoid fever agent <italic>Salmonella</italic> Typhi</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ingle</surname><given-names>Danielle J.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hawkey</surname><given-names>Jane</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hunt</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Iqbal</surname><given-names>Zamin</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Keane</surname><given-names>Jacqueline A.</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Afolayan</surname><given-names>Ayorinde O.</given-names></name><xref ref-type="aff" rid="A9">9</xref><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Niyaz</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Andleeb</surname><given-names>Saadia</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Ashton</surname><given-names>Philip M.</given-names></name><xref ref-type="aff" rid="A13">13</xref><xref ref-type="aff" rid="A14">14</xref></contrib><contrib contrib-type="author"><name><surname>Bogoch</surname><given-names>Isaac I.</given-names></name><xref ref-type="aff" rid="A15">15</xref></contrib><contrib contrib-type="author"><name><surname>Carey</surname><given-names>Megan E.</given-names></name><xref ref-type="aff" rid="A16">16</xref><xref ref-type="aff" rid="A17">17</xref></contrib><contrib contrib-type="author"><name><surname>Chattaway</surname><given-names>Marie Anne</given-names></name><xref ref-type="aff" rid="A18">18</xref></contrib><contrib contrib-type="author"><name><surname>Crump</surname><given-names>John A.</given-names></name><xref ref-type="aff" rid="A19">19</xref></contrib><contrib contrib-type="author"><name><surname>Guevara</surname><given-names>Paula Diaz</given-names></name><xref ref-type="aff" rid="A20">20</xref></contrib><contrib contrib-type="author"><name><surname>Howden</surname><given-names>Benjamin P.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A21">21</xref><xref ref-type="aff" rid="A22">22</xref></contrib><contrib contrib-type="author"><name><surname>Izumiya</surname><given-names>Hidemasa</given-names></name><xref ref-type="aff" rid="A23">23</xref></contrib><contrib contrib-type="author"><name><surname>Jacob</surname><given-names>Jobin John</given-names></name><xref ref-type="aff" rid="A24">24</xref></contrib><contrib contrib-type="author"><name><surname>Judd</surname><given-names>Louise M.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A22">22</xref></contrib><contrib contrib-type="author"><name><surname>Kapil</surname><given-names>Arti</given-names></name><xref ref-type="aff" rid="A25">25</xref></contrib><contrib contrib-type="author"><name><surname>Keddy</surname><given-names>Karen H.</given-names></name><xref ref-type="aff" rid="A26">26</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Justin Y.</given-names></name><xref ref-type="aff" rid="A27">27</xref></contrib><contrib contrib-type="author"><name><surname>Levine</surname><given-names>Myron M.</given-names></name><xref ref-type="aff" rid="A28">28</xref></contrib><contrib contrib-type="author"><name><surname>Morita</surname><given-names>Masatomo</given-names></name><xref ref-type="aff" rid="A23">23</xref></contrib><contrib contrib-type="author"><name><surname>Nair</surname><given-names>Satheesh</given-names></name><xref ref-type="aff" rid="A18">18</xref></contrib><contrib contrib-type="author"><name><surname>Octavia</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="A29">29</xref></contrib><contrib contrib-type="author"><name><surname>Okeke</surname><given-names>Iruka N.</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Osadebamwen</surname><given-names>Precious E.</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Rahman</surname><given-names>Sadia Isfat Ara</given-names></name><xref ref-type="aff" rid="A30">30</xref></contrib><contrib contrib-type="author"><name><surname>Rokney</surname><given-names>Assaf</given-names></name><xref ref-type="aff" rid="A31">31</xref></contrib><contrib contrib-type="author"><name><surname>Rasko</surname><given-names>David A.</given-names></name><xref ref-type="aff" rid="A28">28</xref><xref ref-type="aff" rid="A32">32</xref></contrib><contrib contrib-type="author"><name><surname>Shamanna</surname><given-names>Varun</given-names></name><xref ref-type="aff" rid="A33">33</xref></contrib><contrib contrib-type="author"><name><surname>Sikorski</surname><given-names>Michael J.</given-names></name><xref ref-type="aff" rid="A28">28</xref><xref ref-type="aff" rid="A32">32</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Anthony M.</given-names></name><xref ref-type="aff" rid="A34">34</xref><xref ref-type="aff" rid="A35">35</xref></contrib><contrib contrib-type="author"><name><surname>Sunmonu</surname><given-names>Gabriel T.</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Tagg</surname><given-names>Kaitlin A.</given-names></name><xref ref-type="aff" rid="A27">27</xref></contrib><contrib contrib-type="author"><name><surname>Wick</surname><given-names>Ryan R.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Dyson</surname><given-names>Zoe A.</given-names></name><xref ref-type="aff" rid="A16">16</xref><xref ref-type="aff" rid="A36">36</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Holt</surname><given-names>Kathryn E.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A16">16</xref><on-behalf-of>M.</on-behalf-of></contrib></contrib-group><contrib-group><contrib contrib-type="author"><collab>Global Typhoid Genomics Consortium <contrib-group><contrib contrib-type="author"><name><surname>Abbas</surname><given-names>Ali H.</given-names></name><xref ref-type="aff" rid="A37">1</xref></contrib><contrib contrib-type="author"><name><surname>Razzak</surname><given-names>Safina Abdul</given-names></name><xref ref-type="aff" rid="A38">2</xref></contrib><contrib contrib-type="author"><name><surname>Aworh</surname><given-names>Mabel K.</given-names></name><xref ref-type="aff" rid="A39">3</xref></contrib><contrib contrib-type="author"><name><surname>Baker</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="A40">4</xref></contrib><contrib contrib-type="author"><name><surname>Basnyat</surname><given-names>Buddha</given-names></name><xref ref-type="aff" rid="A41">5</xref></contrib><contrib contrib-type="author"><name><surname>Chew</surname><given-names>Ka Lip</given-names></name><xref ref-type="aff" rid="A42">6</xref></contrib><contrib contrib-type="author"><name><surname>Darton</surname><given-names>Thomas C.</given-names></name><xref ref-type="aff" rid="A43">7</xref></contrib><contrib contrib-type="author"><name><surname>Greenhill</surname><given-names>Andrew R.</given-names></name><xref ref-type="aff" rid="A44">8</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Madhu</given-names></name><xref ref-type="aff" rid="A45">9</xref></contrib><contrib contrib-type="author"><name><surname>Hatta</surname><given-names>Mochammad</given-names></name><xref ref-type="aff" rid="A46">10</xref></contrib><contrib contrib-type="author"><name><surname>Ikram</surname><given-names>Aamer</given-names></name><xref ref-type="aff" rid="A47">11</xref></contrib><contrib contrib-type="author"><name><surname>Jinka</surname><given-names>Dasaratha Ramaiah</given-names></name><xref ref-type="aff" rid="A48">12</xref></contrib><contrib contrib-type="author"><name><surname>Lauer</surname><given-names>A. C.</given-names></name><xref ref-type="aff" rid="A49">13</xref></contrib><contrib contrib-type="author"><name><surname>Lunguya</surname><given-names>Octavie</given-names></name><xref ref-type="aff" rid="A50">14</xref></contrib><contrib contrib-type="author"><name><surname>Mahindroo</surname><given-names>Jaspreet</given-names></name><xref ref-type="aff" rid="A51">15</xref></contrib><contrib contrib-type="author"><name><surname>Mashe</surname><given-names>Tapfumanei</given-names></name><xref ref-type="aff" rid="A52">16</xref></contrib><contrib contrib-type="author"><name><surname>Mylona</surname><given-names>Elli</given-names></name><xref ref-type="aff" rid="A53">17</xref></contrib><contrib contrib-type="author"><name><surname>de la Gandara</surname><given-names>Maria Pardos</given-names></name><xref ref-type="aff" rid="A54">18</xref></contrib><contrib contrib-type="author"><name><surname>Pollard</surname><given-names>Andrew J.</given-names></name><xref ref-type="aff" rid="A55">19</xref></contrib><contrib contrib-type="author"><name><surname>Rahman</surname><given-names>Saikt</given-names></name><xref ref-type="aff" rid="A56">20</xref></contrib><contrib contrib-type="author"><name><surname>Redwan</surname><given-names>Elrashdy M</given-names></name><xref ref-type="aff" rid="A57">21</xref><xref ref-type="aff" rid="A58">22</xref><xref ref-type="aff" rid="A59">23</xref></contrib><contrib contrib-type="author"><name><surname>Rutanga</surname><given-names>Jean Pierre</given-names></name><xref ref-type="aff" rid="A60">24</xref></contrib><contrib contrib-type="author"><name><surname>Shakya</surname><given-names>Jivan</given-names></name><xref ref-type="aff" rid="A61">25</xref></contrib><contrib contrib-type="author"><name><surname>Tanmoy</surname><given-names>Arif</given-names></name><xref ref-type="aff" rid="A62">26</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Mathew S.</given-names></name><xref ref-type="aff" rid="A63">27</xref></contrib><contrib contrib-type="author"><name><surname>Van Puyvelde</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="A64">28</xref></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>Jacqueline M</given-names></name><xref ref-type="aff" rid="A65">29</xref></contrib></contrib-group></collab></contrib></contrib-group><aff id="A1"><label>1</label>The Department of Microbiology and Immunology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>The University of Melbourne</institution></institution-wrap> at <institution-wrap><institution-id institution-id-type="ror">https://ror.org/016899r71</institution-id><institution>The Peter Doherty Institute</institution></institution-wrap> for Infection and Immunity, <city>Melbourne</city>, <country country="AU">Australia</country></aff><aff id="A2"><label>2</label>Department of Infectious Diseases, School of Translational Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02bfwt286</institution-id><institution>Monash University</institution></institution-wrap>, <city>Melbourne</city>, <state>Victoria</state><postal-code>3004</postal-code>, <country country="AU">Australia</country></aff><aff id="A3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03mstc592</institution-id><institution>European Molecular Biology Laboratory</institution></institution-wrap> - <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02catss52</institution-id><institution>European Bioinformatics Institute</institution></institution-wrap>, <city>Hinxton, Cambridge</city>, <country country="GB">United Kingdom</country></aff><aff id="A4"><label>4</label>Nuffield Department of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap>, <city>Oxford</city>, <country country="GB">United Kingdom</country></aff><aff id="A5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00aps1a34</institution-id><institution>National Institute of Health Research Oxford Biomedical Research Centre</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0080acb59</institution-id><institution>John Radcliffe Hospital</institution></institution-wrap>, <addr-line>Headley Way</addr-line>, <city>Oxford</city>, <country country="GB">United Kingdom</country></aff><aff id="A6"><label>6</label>Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap>, <city>Oxford</city>, <country country="GB">United Kingdom</country></aff><aff id="A7"><label>7</label>Milner Centre for Evolution, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/002h8g185</institution-id><institution>University of Bath</institution></institution-wrap>, <country country="GB">United Kingdom</country></aff><aff id="A8"><label>8</label>Department of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap>, Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, <addr-line>Cambridge Biomedical Campus</addr-line>, <country country="GB">United Kingdom</country></aff><aff id="A9"><label>9</label>Faculty of Pharmacy and College of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wx2rr30</institution-id><institution>University of Ibadan</institution></institution-wrap>, <city>Ibadan</city>, <country country="NG">Nigeria</country></aff><aff id="A10"><label>10</label>Institute for Infection Prevention and Control, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vzbgh69</institution-id><institution>Freiburg University Medical Centre</institution></institution-wrap>, <city>Freiburg</city>, <country country="DE">Germany</country></aff><aff id="A11"><label>11</label>Pathogen Biology Laboratory, Department of Biotechnology and Bioinformatics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a7rxb17</institution-id><institution>University of Hyderabad</institution></institution-wrap>, <city>Hyderabad</city>, <country country="IN">India</country></aff><aff id="A12"><label>12</label>Atta-ur-Rahman School of Applied Biosciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03w2j5y17</institution-id><institution>National University of Sciences and Technolog</institution></institution-wrap>, <country country="PK">Pakistan</country></aff><aff id="A13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03tebt685</institution-id><institution>Malawi Liverpool Wellcome Programme</institution></institution-wrap>, <city>Blantyre</city>, <country country="MW">Malawi</country></aff><aff id="A14"><label>14</label>Institute of Infection, Ecology and Veterinary Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04xs57h96</institution-id><institution>University of Liverpool</institution></institution-wrap>, <city>Liverpool</city>, <country country="GB">UK</country></aff><aff id="A15"><label>15</label>Department of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto</institution></institution-wrap>, <country country="CA">Canada</country></aff><aff id="A16"><label>16</label>Department Infection Biology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a0jsq62</institution-id><institution>London School of Hygiene and Tropical Medicine</institution></institution-wrap>, <city>London</city>, <country country="GB">UK</country></aff><aff id="A17"><label>17</label>IAVI, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/038zxea36</institution-id><institution>Chelsea &amp; Westminster Hospital</institution></institution-wrap>, <city>London</city>, <country country="GB">United Kingdom</country></aff><aff id="A18"><label>18</label>Gastrointestinal Bacteria Reference Unit, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/018h10037</institution-id><institution>United Kingdom Health Security Agency</institution></institution-wrap>, <city>London</city>, <country country="GB">United Kingdom</country></aff><aff id="A19"><label>19</label>Centre for International Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01jmxt844</institution-id><institution>University of Otago</institution></institution-wrap>, <city>Dunedin</city>, <country country="NZ">New Zealand</country></aff><aff id="A20"><label>20</label>Grupo de Microbiologia, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03gx6zj11</institution-id><institution>Instituto Nacional de Salud</institution></institution-wrap>, <city>Bogota</city>, <country country="CO">Colombia</country></aff><aff id="A21"><label>21</label>Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology &amp; Immunology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>The University of Melbourne</institution></institution-wrap> at <institution-wrap><institution-id institution-id-type="ror">https://ror.org/016899r71</institution-id><institution>The Peter Doherty Institute</institution></institution-wrap> for Infection and Immunity, <city>Melbourne</city>, <country country="AU">Australia</country></aff><aff id="A22"><label>22</label>Innovation Hub, Centre for Pathogen Genomics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>University of Melbourne (Doherty Institute)</institution></institution-wrap></aff><aff id="A23"><label>23</label>Department of Bacteriology I, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/001ggbx22</institution-id><institution>National Institute of Infectious Diseases</institution></institution-wrap>, <city>Tokyo</city>, <country country="JP">Japan</country></aff><aff id="A24"><label>24</label>Department of Clinical Microbiology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00c7kvd80</institution-id><institution>Christian Medical College</institution></institution-wrap>, <city>Vellore</city>, <country country="IN">India</country></aff><aff id="A25"><label>25</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02dwcqs71</institution-id><institution>All India Institute of Medical Sciences</institution></institution-wrap>, <city>New Delhi</city>, <country country="IN">India</country></aff><aff id="A26"><label>26</label>Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00g0p6g84</institution-id><institution>University of Pretoria</institution></institution-wrap>, <country country="ZA">South Africa</country></aff><aff id="A27"><label>27</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042twtr12</institution-id><institution>Centers for Disease Control and Prevention</institution></institution-wrap>, <city>Atlanta</city>, <country country="US">United States of America</country></aff><aff id="A28"><label>28</label>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, United States of America</aff><aff id="A29"><label>29</label>School of Biotechnology and Biomolecular Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>University of New South Wales</institution></institution-wrap>, <city>Sydney</city>, <country country="AU">Australia</country></aff><aff id="A30"><label>30</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04vsvr128</institution-id><institution>International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b)</institution></institution-wrap>, <country country="BD">Bangladesh</country></aff><aff id="A31"><label>31</label>Ministry of Health, Jerusalem, Israel</aff><aff id="A32"><label>32</label>Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, United States of America</aff><aff id="A33"><label>33</label>Central Research Laboratory, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04pcmf738</institution-id><institution>KIMS</institution></institution-wrap>, <city>Bengaluru</city>, <country country="IN">India</country></aff><aff id="A34"><label>34</label>Centre for Enteric Diseases, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/007wwmx82</institution-id><institution>National Institute for Communicable Diseases</institution></institution-wrap>, <city>Johannesburg</city>, <country country="ZA">South Africa</country></aff><aff id="A35"><label>35</label>Department of Medical Microbiology, Faculty of Health Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00g0p6g84</institution-id><institution>University of Pretoria</institution></institution-wrap>, <city>Pretoria</city>, <country country="ZA">South Africa</country></aff><aff id="A36"><label>36</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05cy4wa09</institution-id><institution>Wellcome Sanger Institute</institution></institution-wrap>, <addr-line>Wellcome Genome Campus</addr-line>, <city>Hinxton</city>, <country country="GB">United Kingdom</country></aff><aff id="A37"><label>1</label>Department of Microbiology, Faculty of Veterinary Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02dwrdh81</institution-id><institution>University of Kufa</institution></institution-wrap>, <addr-line>Kufa-Najaf Street</addr-line>, <city>Najaf</city>, <country country="IQ">Iraq</country></aff><aff id="A38"><label>2</label>Department of Paediatrics and Child Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03gd0dm95</institution-id><institution>Aga Khan University</institution></institution-wrap>, <postal-code>P.O. Box 3500</postal-code>, <addr-line>National Stadium Rd, Karachi</addr-line>, <city>Sindh</city>, <country country="PK">Pakistan</country></aff><aff id="A39"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tj63d06</institution-id><institution>North Carolina State University</institution></institution-wrap>, <addr-line>1060 William Moore Drive</addr-line>, <city>Raleigh</city>, <state>NC</state><postal-code>27607</postal-code>, <country country="US">USA</country></aff><aff id="A40"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap>, JCBC, <addr-line>Puddicome way</addr-line>, <city>Cambridge</city>, <postal-code>CB2 0AW</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A41"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03hwx9w41</institution-id><institution>OUCRU-Nepal</institution></institution-wrap>, <city>Jhamshikhel, Lalitpur</city>, <country country="NP">Nepal</country></aff><aff id="A42"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04fp9fm22</institution-id><institution>National University Hospital</institution></institution-wrap>, <addr-line>5 Lower Kent Ridge Road</addr-line>, <city>Singapore</city><postal-code>119074</postal-code>, <country country="SG">Republic of Singapore</country></aff><aff id="A43"><label>7</label>Clinical Infection Research Group, School of Medicine and Population Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05krs5044</institution-id><institution>University of Sheffield</institution></institution-wrap>, <addr-line>Western Bank</addr-line>, <city>Sheffield</city>, <postal-code>S10 2TN</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A44"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05qbzwv83</institution-id><institution>Federation University Australia</institution></institution-wrap>, <addr-line>Gippsland Campus</addr-line>, Churchill, <state>Victoria</state>, <country country="AU">Australia</country></aff><aff id="A45"><label>9</label>Postgraduate Institute of Medical Education and Research, sector 12, Chandigarh. CMC Vellore, India</aff><aff id="A46"><label>10</label>Department of Molecular Biology and Immunology, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00da1gf19</institution-id><institution>Hasanuddin University</institution></institution-wrap>, <city>Makassar</city>, <postal-code>90245</postal-code>, <country country="ID">Indonesia</country></aff><aff id="A47"><label>11</label>Fauji Foundation, Rawal Road, Rawalpindi, Pakistan</aff><aff id="A48"><label>12</label>RDT Hospital, Bathalapalli, Srisathya Sai District, 515661, India</aff><aff id="A49"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042twtr12</institution-id><institution>Centers for Disease Control and Prevention</institution></institution-wrap>, <city>Atlanta</city>, <country country="US">United States of America</country></aff><aff id="A50"><label>14</label>Department of Microbiology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03qyfje32</institution-id><institution>Institut National de Recherche Biomédicale</institution></institution-wrap>, <city>Kinshasa</city>, <country country="CG">Democratic Republic of the Congo</country></aff><aff id="A51"><label>15</label>MRC Centre for Global Infectious Disease Analysis, School of Public Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, <city>London</city>, <postal-code>W12 0BZ</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A52"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01m294726</institution-id><institution>World Health Organisation</institution></institution-wrap>, <country country="ZW">Zimbabwe</country></aff><aff id="A53"><label>17</label>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap>, <city>Cambridge</city><postal-code>CB1 0AW</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A54"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0495fxg12</institution-id><institution>Institut Pasteur</institution></institution-wrap>, <country country="FR">France</country></aff><aff id="A55"><label>19</label>Oxford Vaccine Group, Department of Paediatrics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap> and the NIHR Oxford Biomedical Research Centre, <city>Oxford</city>, <country country="GB">UK</country></aff><aff id="A56"><label>20</label>RDT Hospital, Bathalapalli, Srisathya Sai District, 515661, India</aff><aff id="A57"><label>21</label>Department of Biological Science, Faculty of Science, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ma4wv74</institution-id><institution>King Abdulaziz University</institution></institution-wrap>, <city>Jeddah</city>, <country country="GB">Saudi Arabia</country></aff><aff id="A58"><label>22</label>Centre of Excellence in Bionanoscience Research, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ma4wv74</institution-id><institution>King Abdulaziz University</institution></institution-wrap>, <city>Jeddah</city><postal-code>21589</postal-code>, <country country="SA">Saudi Arabia</country></aff><aff id="A59"><label>23</label>Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pft3n23</institution-id><institution>City of Scientific Research and Technological Applications</institution></institution-wrap>, <addr-line>New Borg EL-Arab</addr-line><postal-code>21934</postal-code>, <city>Alexandria</city>, <country country="EG">Egypt</country></aff><aff id="A60"><label>24</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00286hs46</institution-id><institution>University of Rwanda</institution></institution-wrap>, <addr-line>KK 737 street</addr-line>, <city>Kigali</city>, <postal-code>B.P 3900</postal-code>, <country country="RW">Rwanda</country></aff><aff id="A61"><label>25</label>Institute for Research in Science and Technology, Sachal-2, Lalitpur, Nepal</aff><aff id="A62"><label>26</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04eak0r73</institution-id><institution>Child Health Research Foundation</institution></institution-wrap>, <city>Dhaka</city>, <country country="BD">Bangladesh</country></aff><aff id="A63"><label>27</label>CMAI, ICMDA</aff><aff id="A64"><label>28</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008x57b05</institution-id><institution>University of Antwerp</institution></institution-wrap>, <city>Antwerp</city>, <country country="BE">Belgium</country></aff><aff id="A65"><label>29</label>Institute of Environmental Sciences and Research 27 Creyke Road, Christchurch, 8041, New Zealand</aff><author-notes><corresp id="CR1"><bold>Correspondence:</bold> Danielle J. Ingle: <email>danielle.ingle@unimelb.edu.au</email>; Zoe A. Dyson: <email>zoe.dyson@lshtm.ac.uk</email>; Kathryn E. Holt: <email>kat.holt@lshtm.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>04</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>30</day><month>09</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Background</title><p id="P1">Typhoid fever results from systemic infection with <italic>Salmonella enterica</italic> serovar Typhi (Typhi) and causes 10 million illnesses annually. Disease control relies on prevention (water, sanitation, and hygiene interventions or vaccination) and effective antimicrobial treatment. Antimicrobial resistant (AMR) Typhi lineages have emerged and become established in many parts of the world. Knowledge of local pathogen populations informed by genomic surveillance, including of lineages (defined by the GenoTyphi scheme) and AMR determinants, is increasingly used to inform local treatment guidelines and to inform vaccination strategy. Current tools for genotyping Typhi require multiple read alignment or assembly steps and have not been validated for analysis of data generated with Oxford Nanopore Technologies (ONT) long-read sequencing devices. Here, we introduce Typhi Mykrobe, a command line software tool for rapid genotyping of Typhi lineages, AMR determinants, and plasmid replicons direct from sequencing reads.</p></sec><sec id="S2"><title>Results</title><p id="P2">We validated Typhi Mykrobe lineage genotyping by comparison with the current standard read mapping-based approach and demonstrated 99.8% concordance across nearly 13,000 genomes sequenced with Illumina platforms. For the few isolates with discordant calls, we show that Typhi Mykrobe results are better supported by the evidence from raw sequence read data than the results generated using the mapping-based approach. We also demonstrate 99.9% concordance for detection of AMR determinants compared with the current standard assembly-based approach, with similar results for plasmid marker detection. Typhi Mykrobe predicts clinical resistance categorisation (S/I/R) for eight drug classes, and we show strong agreement with phenotypic categorisations generated from reference laboratory minimum inhibitory concentration (MIC) data for n=1,572 Illumina-sequenced isolates (&gt;99% agreement within one doubling dilution). Using n=100 isolates sequenced with both Illumina and ONT, we show strong concordance (&gt;96% for genotype and &gt;98% for AMR and plasmid) between calls made from ONT reads and those made from Illumina reads. Typhi Mykrobe takes less than a minute per sample and is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link>.</p></sec><sec id="S3"><title>Conclusions</title><p id="P3">Typhi Mykrobe provides rapid and sensitive genotyping of Typhi genomes direct from Illumina and ONT reads. It demonstrated accurate assignment of GenoTyphi lineage, detection of AMR determinants and prediction of corresponding AMR phenotypes, and identification of plasmid replicons.</p></sec></abstract><kwd-group><kwd>Typhoid fever</kwd><kwd><italic>Salmonella</italic> Typhi</kwd><kwd>Antimicrobial Resistance (AMR)</kwd><kwd>Whole Genome Sequencing (WGS)</kwd><kwd>pathogen sequencing</kwd><kwd>genotyping</kwd><kwd>lineage</kwd></kwd-group></article-meta></front><body><sec id="S4" sec-type="intro"><title>Background</title><p id="P4">Typhoid fever is caused by systemic infection with the human-restricted bacterium <italic>Salmonella enterica</italic> subspecies <italic>enterica</italic> serovar Typhi (Typhi) [<xref ref-type="bibr" rid="R1">1</xref>]. More than 10 million typhoid fever illnesses occur annually (mainly in south Asia), associated with 100,000 deaths, and the risk of complications and death increases without effective antimicrobial therapy [<xref ref-type="bibr" rid="R2">2</xref>]. The World Health Organization AWaRe (Access, Watch, Reserve) Antibiotic guidance recommends typhoid fever is treated with ciprofloxacin, unless resistance is prevalent locally, in which case azithromycin is recommended to treat uncomplicated disease and intravenous ceftriaxone is recommended for treatment of severe disease [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>]. A high proportion of typhoid fever is caused by antimicrobial resistant (AMR) Typhi, and nearly all Typhi isolated in south Asia have been ciprofloxacin non-susceptible for over two decades [<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref>]. Extensively drug resistant (XDR, resistant to amoxicillin/ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, ciprofloxacin, and ceftriaxone) Typhi, for which the only treatment options are oral azithromycin or intravenous carbapenems, have been circulating in Pakistan for nearly a decade with travel-associated infections reported globally [<xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref>]. Concerningly, XDR Typhi with no travel links has been reported in USA and China [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R10">10</xref>], and XDR isolates with additional resistance to azithromycin and carbapenems were recently reported in Pakistan [<xref ref-type="bibr" rid="R11">11</xref>].</p><p id="P5">Tracking the emergence and spread of AMR Typhi through whole genome sequencing (WGS) is important to inform public health control measures such as deployment of typhoid conjugate vaccines (TCVs) [<xref ref-type="bibr" rid="R12">12</xref>], investigating and controlling outbreaks [<xref ref-type="bibr" rid="R10">10</xref>], and informing the development of antimicrobial treatment guidance [<xref ref-type="bibr" rid="R3">3</xref>], including management of travel-associated infections in non-endemic countries [<xref ref-type="bibr" rid="R4">4</xref>]. Genetic determinants of AMR are well-understood in Typhi [<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref>], and include both acquired genes that are plasmid-borne or chromosomally integrated [<xref ref-type="bibr" rid="R15">15</xref>], and point mutations in core genes. These include <italic>acrB</italic> for azithromycin resistance [<xref ref-type="bibr" rid="R16">16</xref>], and quinolone resistance-determining regions (QRDR) of <italic>gyrA</italic>, <italic>gyrB,</italic> and <italic>parC</italic> for ciprofloxacin non-susceptibility and resistance [<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R17">17</xref>]. Recently, carbapenem-resistant Typhi was described, due to acquisition of a plasmid-borne carbapenemase gene [<xref ref-type="bibr" rid="R11">11</xref>]. Typhi is highly clonal, which has hampered subtyping in the past; however, its population structure has been well defined using WGS [<xref ref-type="bibr" rid="R15">15</xref>], and the GenoTyphi framework for genotyping and variant nomenclature first proposed in 2016 [<xref ref-type="bibr" rid="R18">18</xref>] has been widely adopted by the global community to facilitate identification of emerging variants and communication across laboratories and settings [<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R21">21</xref>].</p><p id="P6">The GenoTyphi scheme was originally defined based on nearly 2,000 WGS isolates from over 60 countries [<xref ref-type="bibr" rid="R18">18</xref>]. It uses a hierarchical framework based on the global phylogeny, stratifying the Typhi population structure into four primary lineages, 16 clades, and 49 subclades (henceforth referred to as genotypes), based on lineage-specific marker single nucleotide variants (SNVs). Under the GenoTyphi scheme, the lineage known as ‘H58’, which has been associated with the spread of multidrug resistance (MDR, resistant to amoxicillin/ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole) Typhi throughout Asia and into Eastern Africa [<xref ref-type="bibr" rid="R15">15</xref>], was designated genotype 4.3.1. The scheme was later extended to provide further discriminatory power for identifying additional subpopulations of epidemiological importance [<xref ref-type="bibr" rid="R21">21</xref>–<xref ref-type="bibr" rid="R27">27</xref>], such as the XDR Typhi lineage associated with outbreaks in Pakistan (genotype 4.3.1.1.P1) [<xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R27">27</xref>]. The scheme currently includes 87 genotypes [<xref ref-type="bibr" rid="R28">28</xref>], and its future maintenance and development will be managed by a working group within the Global Typhoid Genomics Consortium (<ext-link ext-link-type="uri" xlink:href="https://www.typhoidgenomics.org/">https://www.typhoidgenomics.org/</ext-link>).</p><p id="P7">The GenoTyphi scheme specification consists of a set of marker SNVs defining the hierarchical genotypes, which in principle can be used by any bioinformatics tool to assign genotypes to new genomes. The original GenoTyphi paper [<xref ref-type="bibr" rid="R18">18</xref>] was accompanied by a Python-based pipeline (available at: <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link>) designed for typing Illumina WGS data against the scheme. This implementation requires users to first map short reads or assemblies to the reference sequence of Typhi strain CT18 (accession AL513382.1) [<xref ref-type="bibr" rid="R29">29</xref>], then provide as input the resulting binary alignment map (BAM) or variant call file (VCF). Marker SNVs were identified from these input files and used to assign genomes to genotypes. Functionality was extended to include detection of mutations associated with reduced susceptibility to ciprofloxacin or azithromycin [<xref ref-type="bibr" rid="R22">22</xref>]. This mapping-based approach had various limitations, largely due to the need for users to pre-map their data to a specific reference, which was cumbersome (e.g. some users had issues with mapping tools creating incompatible output files, the BAM files are large and inefficient to process), and AMR analysis was restricted to mutation detection. The GenoTyphi scheme has also been implemented in other genotyping tools, including Typhi PathogenWatch, [<xref ref-type="bibr" rid="R13">13</xref>] which works by analysing assembled genomes, and the split-<italic>k</italic>-mer-based BioHansel tool, which does not include AMR detection [<xref ref-type="bibr" rid="R30">30</xref>].</p><p id="P8">Here, we present a novel approach to rapid genotyping of both AMR and GenoTyphi lineages from reads, implemented in the Mykrobe open-source software framework [<xref ref-type="bibr" rid="R31">31</xref>], dubbed Typhi Mykrobe. Input into this new tool accepts raw WGS reads (FASTQ files), and has been tested with reads generated by ONT and Illumina platforms. The tool performs rapid (i) lineage genotyping using the GenoTyphi framework; (ii) detection of a broad range of clinically relevant molecular determinants of AMR, including both acquired genes and mutations; and (iii) detection of plasmid replicon markers common to Typhi. We validated GenoTyphi lineage assignment from reads by comparison with the original mapping-based implementation, using 12,839 Typhi genomes [<xref ref-type="bibr" rid="R14">14</xref>]. We assessed AMR genotype calls by comparison with assembly-based genotype calls from PathogenWatch, and with antimicrobial susceptibility phenotypes for 4,018 isolates. Finally, we assessed performance on long read data generated using Oxford Nanopore Technologies (ONT) MinION devices, using 93 isolates with matched ONT and Illumina data.</p><sec id="S5"><title>Implementation</title><sec id="S6"><title>Genotyping targets</title><p id="P9">The current scope of the GenoTyphi scheme as discussed here (n=87 genotypes) is illustrated in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>. This includes five new genotypes (3.5.4.1, 3.5.4.2, 3.5.4.3, 4.3.1.2.1, 4.3.1.2.1.1) recently described in a technical report [<xref ref-type="bibr" rid="R28">28</xref>]. The full scheme specification is available in the GenoTyphi repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link>) in the file Genotype_specification.csv.</p><p id="P10">The AMR and plasmid targets included in Typhi Mykrobe are summarised in <xref ref-type="fig" rid="F1">Figure 1</xref>. These include sequence probes targeted to detect presence/absence of epidemiologically relevant mobile AMR determinants [<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref>], conferring resistance to the currently recommended drugs ciprofloxacin, ceftriaxone, and azithromycin, as well as older drugs ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, and tetracycline, as well as carbapenems. Fourteen SNVs associated with resistance to ciprofloxacin and azithromycin are also included. In addition, Typhi Mykrobe includes probes to detect the presence or absence of 13 plasmid replicons previously reported in Typhi [<xref ref-type="bibr" rid="R14">14</xref>], including 11 associated with AMR plasmids, the cryptic plasmid pHCM2, and linear plasmid pBSSB1, which carries the alternative flagellin z66 [<xref ref-type="bibr" rid="R32">32</xref>]. A marker SNV to identify the plasmid sequence type 6 (PST6) lineage of the dominant IncHI1 plasmid is also included [<xref ref-type="bibr" rid="R33">33</xref>]. The full list of AMR targets is available in the GenoTyphi repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link>) in the file AMR_genes_mutations_plasmids.csv.</p></sec><sec id="S7"><title>Implementation in Mykrobe</title><p id="P11">The Mykrobe software, first developed in 2015 for <italic>Mycobacterium tuberculosis</italic> and <italic>Staphylococcus aureus</italic> [<xref ref-type="bibr" rid="R34">34</xref>], uses a <italic>k</italic>-mer-based approach to identify marker SNVs and the presence or absence of target genes using ‘probe’ sequences to screen against [<xref ref-type="bibr" rid="R31">31</xref>]. These data are then used to assign hierarchical genotypes and report AMR determinants. Probe sets have been previously developed and implemented for other bacterial pathogens including <italic>Mycobacterium tuberculosis</italic> [<xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R36">36</xref>], <italic>Staphylococcus aureus</italic> [<xref ref-type="bibr" rid="R31">31</xref>] and <italic>Shigella sonnei</italic> [<xref ref-type="bibr" rid="R37">37</xref>]. Mykrobe is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/Mykrobe-tools/mykrobe">https://github.com/Mykrobe-tools/mykrobe</ext-link>.</p><p id="P12">Mykrobe probe sets were created for genotype and AMR marker SNVs using the <italic>mykrobe variant make-probes</italic> command using a <italic>k</italic>-mer size of 21 and the Typhi CT18 reference genome (accession: AL513382.1). The nested hierarchical relationships of the marker SNVs were specified and Mykrobe used this information to identify the best supported genotype call (e.g., a call of ‘4.3.1.1’ is typically supported by detection of three nested markers that demarcate different levels of the hierarchy: 4, 4.3.1, 4.3.1.1). Briefly, probe sets for gene presence or absence were created using a Python script that extracted the relevant AMR sequences. Details of the specific commands and Python scripts are provided in <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link>. Probe sets were also created to confirm input read sets as <italic>S. enterica</italic> using the presence of marker gene <italic>invA</italic>, involved in invasion of intestinal epithelium cells by <italic>S. enterica</italic>, and serovar Typhi based on the 26 known multi-locus sequence types (STs) (see <xref ref-type="fig" rid="F1">Figure 1</xref>). Further details of the preliminary testing and implementation of the Typhi probe sets are available in the technical report <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/doi/10.5281/zenodo.7407984">https://zenodo.org/doi/10.5281/zenodo.7407984</ext-link>. The Typhi Mykrobe probe sets and typing panel are available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.27102334">https://doi.org/10.6084/m9.figshare.27102334</ext-link>.</p></sec><sec id="S8"><title>Summarising Mykrobe outputs</title><p id="P13">To support interpretation of the Mykrobe output, we developed a Python-based parser script <italic>parse_typhi_mykrobe.py,</italic> which takes as input a set of JavaScript Object Notation (JSON) files output by Mykrobe, and summarises them in a tab-delimited table with one row per genome, and columns to indicate the genotype calls (see <xref ref-type="fig" rid="F1">Figure 1</xref>). Also included are several quality-control fields reported by Mykrobe, including read-level support for each marker SNV contributing to the final genotype call (‘node support’), and for any additional markers detected. This information is helpful for identifying contaminated samples (see examples in <xref ref-type="sec" rid="S13">Results</xref>). The parser script also assigns a summary ‘confidence’ level in the final GenoTyphi lineage call, based on the Mykrobe quality scores for each nested component marker that makes up the final genotype call. In brief, a ‘weak’ confidence call is assigned when one or more marker SNVs are of low quality, defined as Mykrobe quality score of 0 or Mykrobe quality score of 0.5 with minority support (i.e., ≥50% of reads) for the derived allele. A ‘moderate’ confidence call is assigned if one (and only one) marker SNV has a Mykrobe quality score of 0.5 but with majority support (i.e. ?50% of reads) for the derived allele. Otherwise, the genotype call is assigned ‘strong’ confidence.</p><p id="P14">The parser script summarises the AMR markers detected by Mykrobe in the form of a pseudo-antibiogram with one column per drug. Each drug column contains either ‘S’ (indicating no markers detected) or ‘R’ (detected markers). For ciprofloxacin, it is useful to distinguish between low-level resistance (MIC 0.06-0.5 mg/L), which is associated with a single mutation or acquired gene and high-level resistance (MIC &gt;0.5 mg/L), which is associated with combinations of two or more determinants [<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R17">17</xref>], because while both groups are associated with increased fever clearance times and probability of treatment failure compared with susceptible strains, high-level resistance is associated with worse outcomes than low-level resistance [<xref ref-type="bibr" rid="R38">38</xref>]. Current guidelines and terminology for these groups vary, but for simplicity, the Mykrobe parser reports these groups as ‘I’ (for intermediate) and ‘R’, respectively. This matches the current CLSI guidelines (<ext-link ext-link-type="uri" xlink:href="https://clsi.org/standards/products/microbiology/documents/m100/">https://clsi.org/standards/products/microbiology/documents/m100/</ext-link>). However, it should be noted that (i) EUCAST defines the clinical breakpoint for ‘R’ in <italic>Salmonella</italic> spp. as MIC &gt;0.06 mg/L (<ext-link ext-link-type="uri" xlink:href="https://www.eucast.org/clinical_breakpoints">https://www.eucast.org/clinical_breakpoints</ext-link>), which includes both low-level and high-level resistance; and (ii) previous literature has referred to the low-level range as ‘decreased ciprofloxacin susceptibility’ rather than ‘I’ [<xref ref-type="bibr" rid="R39">39</xref>]. In addition to this antibiogram-style summary, individual AMR and plasmid markers are reported in their own columns, coded as 1=present and 0=absent (as seen in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>, available at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe">https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe</ext-link>).</p><p id="P15">All code and instructions for genotyping isolates with GenoTyphi using Typhi Mykrobe are freely available in the GitHub repository at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link> (DOI: 10.5281/zenodo.13859721).</p></sec><sec id="S9"><title>Validation data</title><p id="P16">Validation on Illumina short-read data was conducted using the Global Typhoid Genomics Consortium dataset described in Carey et al [<xref ref-type="bibr" rid="R14">14</xref>]. Reads were mapped to the CT18 reference genome (accession: AL513382) [<xref ref-type="bibr" rid="R29">29</xref>] using bwa-mem v0.7.17 via the Centre for Genomic Pathogen Surveillance (CGPS) mapping pipeline v1.2.2 (<ext-link ext-link-type="uri" xlink:href="https://gitlab.com/cgps/ghru/pipelines/snp_phylogeny">https://gitlab.com/cgps/ghru/pipelines/snp_phylogeny</ext-link>), to generate alignments in BAM format. Assemblies were generated using the CGPS assembly pipeline v2.1.0 (<ext-link ext-link-type="uri" xlink:href="https://gitlab.com/cgps/ghru/pipelines/dsl2/pipelines/assembly/">https://gitlab.com/cgps/ghru/pipelines/dsl2/pipelines/assembly/</ext-link>) which utilises the SPAdes assembler (v3.12.0) [<xref ref-type="bibr" rid="R40">40</xref>,<xref ref-type="bibr" rid="R41">41</xref>]. A total of 141 isolates were excluded due to excessive unclustered heterozygous SNVs indicative of mixed cultures (n=92), assembly issues (n=46) or both (n=3), resulting in 12,839 isolates for Mykrobe validation (listed in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>, available at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe">https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe</ext-link>).</p></sec><sec id="S10"><title>Validation of genotype calls</title><p id="P17">Typhi Mykrobe v0.12.1 was run on all (n=12,839) Illumina FASTQ files using the new Typhi panel (v20221208) and the results were summarised using <italic>parse_typhi_mykrobe.py</italic>. To validate Typhi Mykrobe’s GenoTyphi genotype calls, we compared them with those called by the original mapping-based approach. To do this, we used BAM file read alignments generated from the same n=12,839 FASTQs as described above as input to the Python script genotyphi.py (v2.0; available at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link>) [<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R28">28</xref>]. To validate the AMR and plasmid calls, we compared them to those called in corresponding genome assemblies by Pathogenwatch (available for n=11,992 genomes, assemblies for the other genomes were excluded as they did not meet Pathogenwatch quality-control criteria[<xref ref-type="bibr" rid="R13">13</xref>]). We downloaded the GenoTyphi, AMR, and plasmid replicon typing reports generated by Basic Local Alignment Search Tool (BLAST) searching assemblies for these genomes from Pathogenwatch on 7 March 2023 (GenoTyphi v20221208 specification for lineage genotypes). Categorical agreement (percentage of genomes where both tools agreed on the same call of presence or absence) was calculated separately for each marker, and collectively by drug (percentage of genomes where both tools agreed that at least one marker was present or that no markers were present) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>, available at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe">https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe</ext-link>). Probes for plasmid-borne carbapenemase genes circulating in Enterobacterales (<italic>bla</italic>NDM-5, <italic>bla</italic>KPC-2, <italic>bla</italic>VIM-1, <italic>bla</italic>IMP-27, <italic>bla</italic>OXA-48) were added to GenoTyphi v20240407 (DOI: 10.5281/zenodo.13859721) following the report of <italic>bla</italic>NDM-5 in Typhi from Pakistan [<xref ref-type="bibr" rid="R11">11</xref>], and validated using the genomes of the two distinct morphologic variants from that study (accessions: SRR22801766 and SRR22801806). Comparisons and statistical analyses were conducted in R v4.1.0 using tidyverse v1.3.1 [<xref ref-type="bibr" rid="R42">42</xref>].</p></sec><sec id="S11"><title>Accuracy of AMR phenotype prediction</title><p id="P18">Antimicrobial susceptibility testing (AST) data were available for n=3,970 of the Illumina-sequenced isolates, sourced from three separate datasets (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 4</xref>, available at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe">https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe</ext-link>). Minimum inhibitory concentration (MIC) data were available from the UK Health Security Agency (UKHSA) for n=852 isolates following EUCAST standards and interpretive criteria (v10, 2020) [<xref ref-type="bibr" rid="R43">43</xref>] and the US Centers for Disease Control and Prevention (US CDC) for n=720 isolates following CLSI standards and interpretive criteria (M100, 2023) [<xref ref-type="bibr" rid="R44">44</xref>]. Disk diffusion data following EUCAST standards and interpretive criteria (v8.0, 2018) were available for n=2,446 isolates collected and analysed from three countries as part of the Surveillance for Enteric Fever in Asia Project (SEAP), with multiple source labs contributing AST data and isolates for sequencing [<xref ref-type="bibr" rid="R6">6</xref>]. Typhi Mykrobe AMR calls following the S/I/R categorisation described above were compared with the phenotypic antimicrobial susceptibility S/I/R categorisation using the relevant CLSI or EUCAST standards for each data set, for the currently recommended drugs azithromycin and ciprofloxacin and ceftriaxone, and the older drugs ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, and tetracycline (note UKHSA tested amoxicillin rather than ampicillin; and SEAP did not test tetracycline). To assess concordance between genotype and phenotype, we followed the principles used for assessment of new AST devices by the US Food and Drug Administration (FDA), which considers (i) categorical agreement, (ii) major error rate (defined as the proportion of S isolates that test R with the new method [<xref ref-type="bibr" rid="R45">45</xref>,<xref ref-type="bibr" rid="R46">46</xref>]), and (iii) very major error rate (defined as the proportion of R isolates that test S with the new method) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 5</xref>, available at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe">https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe</ext-link>). The FDA standard requires &gt;90% overall categorical agreement (within one doubling dilution), &lt;3% major errors for each drug, and &lt;1.5% very major errors for each drug; hence, we adopted these thresholds to assess the accuracy of the genotype-based prediction of phenotype. For drugs with high error rates, we investigated the relationship between individual resistance markers and phenotype, which we visualised using upset plots generated in R v4.1.0 using the ComplexUpset package v1.3.3 (10.5281/zenodo.3700590). For five isolates with unexplained trimethoprim-sulfamethoxazole resistance, we used nucleotide blast search of the genome assemblies to confirm the presence of wild-type chromosomal <italic>folA</italic> and <italic>folP</italic> (100% nucleotide match to reference sequences from Typhi strain Ty2) and screened the assemblies for other AMR determinants using CARD RGI v6.0.3 [<xref ref-type="bibr" rid="R47">47</xref>].</p></sec><sec id="S12"><title>Matched ONT and Illumina validation data</title><p id="P19">For 93 isolates, long-read ONT data were available in addition to the Illumina data; these included 68 isolates from Carey et al 2023 [<xref ref-type="bibr" rid="R14">14</xref>] and 30 novel isolates from this study. Sample-level details including accessions and technical specifications such as library, flow cell, device, basecaller, and ONT processing (including demultiplexing, trimming and filtering), are available in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 6</xref>, available at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe">https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe</ext-link>. These varied between isolates including different flow cells (e.g., R9.4.1, n=30 and R10.4.1, n=24) and base calling methods. Read depth for each ONT dataset was assessed by using seqtk v1.2-r94 (<ext-link ext-link-type="uri" xlink:href="https://github.com/lh3/seqtk">https://github.com/lh3/seqtk</ext-link>) to determine total number of bases per read set, which was divided by the length of the CT18 reference genome (4,809,037 bases). For four genomes, ONT reads were assembled to resolve discrepant plasmid calls, assembly was done using Flye v2.9.1-b1780 [<xref ref-type="bibr" rid="R48">48</xref>] with default parameters and yielding genome sizes of the expected 4.8 Mbp. Due to the high read depth (784×), the ONT data for SRR17299234 was subsampled prior to assembly using Filtlong v0.2.1 (<ext-link ext-link-type="uri" xlink:href="https://github.com/rrwick/Filtlong">https://github.com/rrwick/Filtlong</ext-link>) to --target_bases 480000000 (resulting in 99.81× depth).</p></sec></sec></sec><sec id="S13" sec-type="results"><title>Results</title><sec id="S14"><title>Validation of GenoTyphi genotype calling</title><p id="P20">To validate Typhi Mykrobe for assigning hierarchical GenoTyphi genotypes, we ran it on n=12,839 Illumina readsets and compared the resulting genotypes to those called using the original mapping-based implementation. Five genomes were typed as ‘not Typhi’ by Mykrobe and not analysed further. Of the remaining n=12,834 genomes, Mykrobe called the same single genotype as the mapping-based approach for n=12,807 (99.79%). For a further n=17 genomes, Mykrobe and the mapping-based pipeline gave concordant reports of two genotypes being present, consistent with mixed samples (in the Typhi Mykrobe output this is reported as one primary genotype plus additional markers, while in the mapping-based pipeline the result is reported as a list of supported genotypes). Eight genomes belonged to genotype 3.5.3, which was nested in 3.5.4, breaking the usual hierarchical structure of the scheme. Typhi Mykrobe correctly reported these genomes as genotype 3.5.3 with support for both markers 3.5.4 and 3.5.3, as it has this nested relationship explicitly encoded in its hierarchy; whereas the mapping-based pipeline does not have this logic and incorrectly reported these genomes as genotype 3.5.4.</p><p id="P21">There were two instances of genuine disagreement in the genotype calls generated by Typhi Mykrobe as compared to the mapping-based approach. One isolate (ERR5243665) was called as genotype 2 by Mykrobe with strong confidence (no reads support for any alternative alleles or markers). It was genotyped as 0.1.3, albeit with low support, by the mapping-based approach, but the genotype 2 marker was also detected. This isolate clustered with other genotype 2 isolates in a distance-based phylogeny of genomes from the same study [<xref ref-type="bibr" rid="R6">6</xref>] (see tree at <ext-link ext-link-type="uri" xlink:href="https://pathogen.watch/collection/0z5knw9ic9b-guevara-et-al-2021">https://pathogen.watch/collection/0z5knw9jic9b-guevara-et-al-2021</ext-link>), suggesting that the Mykrobe call is correct. The other isolate (ERR2663783) was called as genotype 4.3.1.1 by Typhi Mykrobe with strong confidence. It was reported as “4.3.1.1,4.3.1.3.Bdq” (with low support) by the mapping approach; however, the support for the 4.3.1.3.Bdq marker was low. This isolate clustered closely with other 4.3.1.1 isolates from the same study [<xref ref-type="bibr" rid="R25">25</xref>](see tree at <ext-link ext-link-type="uri" xlink:href="https://pathogen.watch/collection/b2k6dym3bdyq-tanmoy2018">https://pathogen.watch/collection/b2k6dym3bdyq-tanmoy2018</ext-link>), which is consistent with the Mykrobe call.</p></sec><sec id="S15"><title>Validation of AMR genotyping</title><p id="P22">To assess the accuracy of Mykrobe for detecting the presence of AMR genes and mutations, we compared genotype calls from Mykrobe (called from <italic>k-</italic>mer analysis of reads) with those from Pathogenwatch (called from BLAST analysis of genome assemblies of the same read sets). We found very strong categorical agreement between the two methods at the individual marker level, with 99.88% of the 299,004 marker-genome combinations yielding the same call (summarised in <xref ref-type="table" rid="T2">Table 2</xref>, full details in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>). High concordance was evident for all genetic markers of AMR (98.56–100%, <xref ref-type="table" rid="T2">Table 2</xref>), as well as plasmid replicon markers (99.74–100%, <xref ref-type="table" rid="T3">Table 3</xref>).</p><p id="P23">Both Mykrobe and Pathogenwatch summarise AMR data in terms of a binary phenotype categorization (S/R), assuming the presence of a marker associated with resistance to a drug implies resistance ‘R’, with the exception of ciprofloxacin, where presence of any marker is categorised as ‘I’ and specific combinations of markers are categorised as ‘R’, resulting in three categories S/I/R (see Methods). Categorical agreement was very high between the drug-level categorisations reported by both genotyping tools, with &gt;99.7% agreement (n=2 to 33 discordant genomes) for each drug (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>), and for subsequent categorisation as MDR (99.86%, n=17 discordant) or XDR (99.97%, n=4 discordant).</p></sec><sec id="S16"><title>Validation of AMR phenotype prediction</title><p id="P24">To assess the accuracy of Mykrobe’s genotype-based clinical resistance categorisations, we compared them with AST data, which was available for a subset of n=4,018 isolates (see Methods, <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 4</xref>). These isolates were from three data sets, using different methods (MIC with EUCAST standards, MIC with CLSI standards, disk diffusion with EUCAST standards), hence we analyzed the results from each dataset separately. Categorical agreement was high (&gt;95%) for all drugs across all three datasets, and very high (&gt;99%) for the two sets of reference-laboratory MIC measures (<xref ref-type="fig" rid="F2">Figure 2</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 5</xref>). The only exception was US CDC categorisation of low-level ciprofloxacin resistance (using the CLSI ‘I’ threshold, ≥0.125 to 0.5 mg/L), which showed 97.36% agreement with Mykrobe calls of ‘I’ or ‘R’. This was mainly due to the presence of major errors (susceptible isolates with AMR determinants detected, thus reported as R by Mykrobe, see Methods), whereby n=17 isolates tested susceptible to ciprofloxacin (n=14 with MIC=0.06 mg/L, n=3 with MIC=0.015 mg/L) but Mykrobe detected a known QRDR mutation (<xref ref-type="fig" rid="F3">Figure 3b</xref>); categorical agreement within one doubling dilution was 99.4%.</p><p id="P25">Major errors were infrequent (&lt;3% prevalence) for all drugs in all datasets (<xref ref-type="fig" rid="F2">Figure 2</xref>), except for ciprofloxacin (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 5</xref>). Most of the ciprofloxacin major errors were in isolates whose MIC or disk zone measurement were close to the breakpoint (<xref ref-type="fig" rid="F3">Figures 3</xref>, <xref ref-type="fig" rid="F4">4c</xref>); all carried well-characterized molecular resistance determinants (QRDR mutations and/or <italic>qnr</italic> genes, see <xref ref-type="fig" rid="F3">Figures 3</xref>, <xref ref-type="fig" rid="F4">4c</xref>), and in all but one case the same determinants were also detected in the corresponding genome assemblies by Pathogenwatch (details below).</p><p id="P26">Very major errors (resistant isolates with no AMR determinants detected, thus reported as S by Mykrobe) were also infrequent (&lt;1.5% prevalence) for the reference-laboratory MIC datasets, but errors were higher in the disk diffusion dataset (<xref ref-type="fig" rid="F2">Figure 2</xref>). The only drugs showing major or very major errors compared with the reference-laboratory MIC data were ciprofloxacin and trimethoprim-sulfamethoxazole (<xref ref-type="fig" rid="F2">Figure 2</xref>). For ciprofloxacin, the US CDC categorisation of high-level resistance (using the CLSI ‘R’ threshold, ≥1 mg/L) yielded four very major errors (R isolate called as ‘I’ by Mykrobe). Two had a single mutation detected (<italic>gyrA-</italic>S83F) and two had double QRDR mutations (<italic>gyrA-</italic>S83F plus <italic>gyrA-</italic>D87N or <italic>parC-</italic>S80I) (see <xref ref-type="fig" rid="F3">Figure 3</xref>); Pathogenwatch calls agreed in all instances. Importantly, all four isolates had MIC=1 mg/L, i.e. they agreed with the genotype-based call within one doubling dilution. UKHSA uses the EUCAST standards, which have a single (low-level) breakpoint for ciprofloxacin (R &gt;0.06 mg/L), and this yielded just two major errors (2.9%) and two very major errors (0.26%) (see <xref ref-type="fig" rid="F3">Figure 3</xref>).</p><p id="P27">For trimethoprim-sulfamethoxazole, Mykrobe analysis of the US CDC dataset yielded a single error (R isolate called as S) but the MIC was 4 mg/L, i.e. within one doubling dilution, and the isolate had no <italic>sul</italic> or <italic>dfr</italic> genes that were identified by Mykrobe or Pathogenwatch. Mykrobe analysis of the UKHSA dataset yielded five errors for trimethoprim-sulfamethoxazole; all were R isolates called as S by Mykrobe, which detected <italic>sul</italic> genes but no <italic>dfrA</italic> genes. Interestingly, all five isolates tested susceptible to trimethoprim alone (MIC ≤0.5, well below the &gt;4 mg/L breakpoint), supporting the absence of <italic>dfrA</italic> genes; these were also not detected by Pathogenwatch analysis of the corresponding genome assemblies, or by UKHSA’s internal pipeline [<xref ref-type="bibr" rid="R44">44</xref>]. Further investigation of these genome assemblies confirmed the presence of wild-type <italic>folA</italic> and <italic>folP</italic>, and no additional determinants were reported by CARD RGI (v6.0.3).</p><p id="P28">Mykrobe analysis of the SEAP dataset showed lower overall categorical agreement with AST phenotypes (95.3–98.2%). As the testing was done using disk diffusion, it was not possible to assess the categorical agreement within one doubling dilution of a MIC. However, most of the errors were within 2–4 mm of the breakpoint (see <xref ref-type="fig" rid="F4">Figure 4</xref>), and in all but one instance, the Mykrobe genotype result matched that called by Pathogenwatch from the corresponding genome assemblies. The only exception was a ciprofloxacin resistant isolate (ERR4325960), which Mykrobe reported as carrying <italic>gyrA-</italic>S83F with no other determinants, but Pathogenwatch detected both <italic>gyrA-</italic>S83F and <italic>qnrS</italic> in the assembly.</p></sec><sec id="S17"><title>Validation on nanopore reads</title><p id="P29">We explored the accuracy of Typhi Mykrobe for genotyping ONT long-read data by comparing results from 98 pairs of ONT to Illumina reads generated from the same isolates. Data were contributed by members of the Global Typhoid Genomics Consortium and generated using different library preparation methods and sequencing devices (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 6</xref>). Mykrobe called one Illumina read set and five ONT read sets as non-Typhi (mean ONT read depths estimated as 0.04×, 4.06×, 8.01×, 26.40×, 27.85×), these were excluded from further comparison as Mykrobe does not further genotype once an isolate is called as non-Typhi.</p><p id="P30">Among the n=92 Typhi genomes called from both ONT and Illumina reads, the Typhi Mykrobe genotype lineage calls matched for n=89 (96.7%). For all three discrepant isolates, (all sequenced on R.9 or R.9.4 flowcells), the set of SNV markers detected from ONT reads closely matched those detected from Illumina reads, but with one or two markers missing from the ONT-based calls and no unexpected markers reported resulting in final genotype calls of 4.3.1.1 vs 4.3.1, 4.3.1.2 vs 4.3.1, 2.1.7.2 vs 2.1.7. For the missing markers, Mykrobe reported low and variable ONT read depths, with ranges 3–9, 4–31 and 1–14, suggesting that the errors are likely due to lack of informative ONT reads at the marker loci. Notably, the overall ONT read depths for these were reasonable (mean 35×, 170× and 90× respectively), suggesting the lack of informative reads for genotyping may be caused by contamination from non-Typhi reads, or high error rates resulting in low rates of <italic>k</italic>-mer matching.</p><p id="P31">AMR marker detection from ONT reads was highly concordant with Illumina-based calls, with 98.77% overall agreement across the n=736 isolate-drug combinations (92 isolates across 8 drugs; see <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 7</xref>). There were nine genomes with disagreement of AMR calls; five of these had a marker detected in Illumina reads but not ONT reads (n=1 <italic>catA1</italic>, n=1 <italic>qnr,</italic> n=3 QRDR mutations), three had <italic>gyrB-</italic>464F detected in ONT reads but not Illumina, and one had <italic>gyrA-</italic>S464F detected in Illumina reads and <italic>gyrA-</italic>S83F in ONT. In all nine cases, the Typhi Mykrobe call from Illumina reads matched that from Pathogenwatch analysis of the corresponding assemblies of Illumina reads. There was no overlap between ONT read sets with AMR discrepancies and those with lineage genotype discrepancies. Overall, ONT-based resistance prediction showed complete agreement with Illumina for six of the eight drugs, 98.9% agreement for chloramphenicol resistance, and 91% for ciprofloxacin resistance.</p><p id="P32">Plasmid marker detection from ONT data was also highly concordant with Illumina-based calls, with 99.67% overall agreement across the n=1,196 isolate-marker combinations (92 isolates across 13 markers; see <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 8</xref>). Four genomes had discrepant plasmid marker calls, all with a marker detected from Illumina reads but not from ONT reads. One isolate (DRR070993) had a typical IncHI1 MDR plasmid profile reported from Illumina reads (IncHI1A, IncHI1BR27, IncHI1_ST6 indicating presence of IncHI1-ST6 plasmid, with <italic>catA1</italic>, <italic>dfrA7</italic>, <italic>bla</italic><sub>TEM-1</sub>, <italic>sul1</italic>, <italic>sul2</italic>), but the ONT read profile was missing the <italic>IncHI1A</italic> and <italic>catA1</italic> markers (and missing <italic>catA1</italic> in the corresponding Illumina assembly and a mismatch for <italic>IncHI1A</italic>). The other three isolates had pHCM2 detected in the Illumina reads and in the corresponding assemblies [<xref ref-type="bibr" rid="R14">14</xref>] but not in ONT reads; for these isolates the ONT and Illumina sequencing was done on different DNA extracts so this may reflect plasmid loss in the culture used for ONT sequencing.</p></sec></sec><sec id="S18" sec-type="discussion"><title>Discussion</title><p id="P33">Typhi Mykrobe provides detection and genotyping of key features of clinical and public health importance, including assigning lineages, AMR determinants, and plasmid replicons (<xref ref-type="fig" rid="F1">Figure 1</xref>). Compared with other tools for Typhi genotyping, Mykrobe has the advantage of not requiring any pre-processing, aligning, or assembling of reads, but instead takes as inputs raw FASTQ files. This simplifies bioinformatics workflows and reduces time-to-result as Typhi Mykrobe can return a full genotype profile in typically &lt;1 minute. Importantly, although Typhi Mykrobe is not a QC tool <italic>per se</italic>, it provides useful data on the read-level support for individual genotype markers, which can be used to help identify potentially mixed samples. As a command-line tool that is easy to install locally using Bioconda, Typhi Mykrobe is suitable for research and public health laboratory settings, facilitates standardized reporting of Typhi genotypes without the need to share sequence data, and enables broader access to bioinformatics functionality across a variety of settings.</p><p id="P34">Typhi Mykrobe showed very high genotyping accuracy, for GenoTyphi lineage assignment (<xref ref-type="table" rid="T1">Table 1</xref>), and detection of AMR and plasmid markers (<xref ref-type="table" rid="T2">Tables 2</xref>-<xref ref-type="table" rid="T3">3</xref>), compared with existing genotyping tools. Of note, the included IncY, pO111 and IncFIB for the cryptic pHCM2 replicon targets have recently been shown to be sometimes carried on phage-plasmids [<xref ref-type="bibr" rid="R49">49</xref>,<xref ref-type="bibr" rid="R50">50</xref>], in addition to conjugative plasmids such as the IncY plasmids associated with XDR Typhi [<xref ref-type="bibr" rid="R26">26</xref>]. Future work is required to identify additional targets to delineate the phage-plasmids, and the Typhi Mykrobe software can be readily updated to include new markers.</p><p id="P35">In addition, we show that the panel of AMR markers currently included in Typhi Mykrobe can be used to predict AMR phenotypes with high accuracy, demonstrating very high concordance with S/I/R calls made from reference-laboratory MICs (<xref ref-type="fig" rid="F2">Figure 2</xref>). Concordance was slightly lower when compared with research laboratory disk diffusion data. However, as the phenotypic resistance prevalence rates were similar across the three datasets, it is reasonable to assume that the higher error rates in the disk diffusion dataset compared with the two reference-laboratory MIC datasets most likely reflect comparatively lower accuracy of the disk diffusion phenotype measurements, which are known to yield lower accuracy for some drugs such as azithromycin [<xref ref-type="bibr" rid="R51">51</xref>,<xref ref-type="bibr" rid="R52">52</xref>] and in this case were completed across multiple laboratories. There are currently no formal standards for assessing the accuracy of AMR phenotype predictions from genomic data [<xref ref-type="bibr" rid="R53">53</xref>]; however, applying the standards for FDA licensing of new AST devices, Typhi Mykrobe easily passed the target threshold for categorical agreement (&gt;99% agreement within one doubling dilution for reference-laboratory MIC data, &gt;95% agreement for disk-diffusion data; vs &gt;90% target) (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><p id="P36">Typhi Mykrobe also showed very low rates of major errors and very major errors compared with the reference-laboratory MIC data, and for nearly all drugs these fell below the acceptable thresholds for a new AST device (&lt;3% and &lt;1.5%, respectively) (<xref ref-type="fig" rid="F2">Figure 2</xref>). The exception was trimethoprim-sulfamethoxazole, for which five UKHSA isolates tested resistant but Typhi Mykrobe predicted as susceptible due to a lack of <italic>dfrA</italic> genes, which are thought to be required for resistance to trimethoprim-sulfamethoxazole along with <italic>sul</italic> genes, which were detected in these genomes. Other genotyping tools (Typhi Pathogenwatch, CARD RGI) also could not identify any known mechanisms of resistance to trimethoprim or trimethoprim-sulfamethoxazole in these genomes, and the isolates tested sensitive to trimethoprim. Therefore, we hypothesise these isolates may harbour efflux mutations or a novel mechanism of resistance to trimethoprim-sulfamethoxazole that does not result in resistance to trimethoprim alone. Further analyses to determine the exact resistance mechanism was beyond the scope of this study. Ciprofloxacin showed very low error rates in the UKHSA MIC data, interpreted using the single low-level resistance threshold (MIC &gt;0.06 mg/L) recommended by EUCAST, but slightly higher error rates for the US CDC MIC data, which was interpreted using low-level and high-level resistance thresholds (although still below the acceptable thresholds within one doubling dilution). Carbapenemase genes were added to the Typhi Mykrobe panel, but this resistance is newly emerging and there was only a single carbapenem-resistant isolate sequenced at the time of testing (in which <italic>bla</italic>NDM-5 was correctly identified by Typhi Mykrobe), therefore we could not yet assess accuracy of phenotype prediction for carbapenems.</p><p id="P37">Finally, we demonstrated that Typhi Mykrobe can be used to genotype ONT reads, showing high concordance with results obtained from the analysis of Illumina reads generated from the same isolates (96.74% agreement on GenoTyphi lineage calls, 98.77% on AMR markers and 99.67% on plasmid markers). We did not have suitable data to directly assess ONT-based AMR predictions with AST data. ONT-based and Illumina-based drug-level predictions of AST phenotypes showed high agreement; however, future studies assessing ONT data compared to reference-laboratory MIC data would be useful to confirm the accuracy of ONT data for phenotype prediction. As one might expect, many of the errors occurred in isolates with lower read depth. However, as the matched ONT-Illumina data available for testing were contributed by different laboratories that used different ONT protocols and devices for library preparation, sequencing, and base calling, we were unable to perform a detailed assessment of the impact of read depth and quality on genotyping performance. The accuracy of ONT reads has greatly increased in recent years and are approaching Illumina read accuracy of ~99%; hence modern ONT data would be expected to perform similarly to Illumina data [<xref ref-type="bibr" rid="R54">54</xref>] (doi.org/10.5281/zenodo.10397817). Future studies assessing the impact of read depth and base calling methods on the performance of Typhi Mykrobe on ONT data would be desirable to help guide laboratories on the most appropriate methods and target yield for ONT experiments aiming to produce reliable genomic surveillance data for Typhi.</p></sec><sec id="S19" sec-type="conclusions"><title>Conclusions</title><p id="P38">Typhi Mykrobe provides rapid and accurate genotyping of Typhi genomes directly from Illumina reads, including (i) assignment of GenoTyphi lineage; (ii) detection of AMR determinants and prediction of corresponding AMR phenotypes demonstrating &gt;99% categorical agreement with reference-laboratory MIC data; and (iii) detection of plasmid replicons. The software also performs well on direct genotyping from ONT reads information, although further investigation is needed to assess the accuracy of AMR phenotype prediction.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Materials</label><media xlink:href="EMS199185-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="d23aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S20"><title>Acknowledgements</title><p>MAC and SN are affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Genomics and Enabling Data at University of Warwick in partnership with the UK Health Security Agency (UKHSA). MAC and SN are based at UKHSA. MH is affiliated to the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University. The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or the UK Health Security Agency.</p><p>SIAR from the icddr,b is grateful to the Governments of Bangladesh, and Canada for providing unrestricted support.</p><p>KAT thanks the epidemiology and laboratory partners in state and local health departments. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Names of specific vendors, manufacturers, or products are included for public health and informational purposes; inclusion does not imply endorsement of the vendors, manufacturers, or products by the Centers for Disease Control and Prevention or the US Department of Health and Human Services.</p><p>AMS thanks all participants of the GERMS-SA Laboratory Surveillance Network, South Africa, for submission of clinical isolates of Salmonella species to the National Institute for Communicable Diseases; the surveillance network includes laboratories belonging to the Department of Health (NHLS laboratories) and laboratories that form part of the private sector.</p><p>We thank all the lab members involved in SEFI reference lab activities at CMC Vellore implicated in culture maintenance and ONT data generation.</p><sec id="S21"><title>Funding</title><p>DJI was supported by an Emerging Leadership Fellowship from the National Health and Medical Research Council (NHMRC) of Australia (GNT1195210). ZAD received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie (grant agreement No 845681). KEH received funding from the Wellcome Trust (grant 226432/Z/22/Z). INO was supported by Official Development Assistance (ODA) funding from the NIHR (grant number #16/136/111) and a Calestous Juma Science LeadershipFellowship from the BMGF (INV-036234). AMS is supported by the SEQAFRICA project, funded by the Department of Health and Social Care’s Fleming Fund using UK aid. MJS was supported by BMGF (INV-000049, OPP1161058) and National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (F30AI156973). JAC was supposed by the Bill &amp; Melinda Gates Foundation Typhoid Vaccine Acceleration Consortium (TyVAC, INV-030857). BPH was supported by a NHMRC Leadership Fellowship (GNT1196103). KAT and this work are supported by the Centers for Disease Control and Prevention. MML was supported by BMGF (OPP1194582, INV-000049, and INV-029806). MH was supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with the UK Health Security Agency (UKHSA) (NIHR200915), and supported by the NIHR Biomedical Research Centre, Oxford. DAR is supported by the NIH (U19 AI110802-01, NIH T32AI162579). JJJ was supported by grants from Bill and Melinda Gates Foundation, USA (Investment ID INV-009497 OPP1159351) for the Project, National Surveillance System for Enteric Fever in India.</p><p>This research was funded in part by the Wellcome Trust. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission</p></sec></ack><glossary><title>List of abbreviations</title><def-list><def-item><term>AMR</term><def><p>antimicrobial resistance</p></def></def-item><def-item><term>AST</term><def><p>antimicrobial susceptibility testing</p></def></def-item><def-item><term>CARD</term><def><p>Comprehensive Antibiotic Resistance Database</p></def></def-item><def-item><term>CLSI</term><def><p>Clinical &amp; Laboratory Standards Institute</p></def></def-item><def-item><term>EUCAST</term><def><p>The European Committee on Antimicrobial Susceptibility Testing</p></def></def-item><def-item><term>FDA</term><def><p>United States of America Food and Drug Administration</p></def></def-item><def-item><term>MDR</term><def><p>multidrug resistance</p></def></def-item><def-item><term>MIC</term><def><p>minimum inhibitory concentration</p></def></def-item><def-item><term>ONT</term><def><p>Oxford Nanopore Technologies</p></def></def-item><def-item><term>QRDR</term><def><p>quinolone resistance-determining regions</p></def></def-item><def-item><term>SEAP</term><def><p>Surveillance for Enteric Fever in Asia Project</p></def></def-item><def-item><term>SNV</term><def><p>single nucleotide variants</p></def></def-item><def-item><term>UKHSA</term><def><p>United Kingdom Health Security Agency</p></def></def-item><def-item><term>US CDC</term><def><p>United States of America Centres for Disease Control and Prevention</p></def></def-item><def-item><term>WGS</term><def><p>whole genome sequencing</p></def></def-item><def-item><term>XDR</term><def><p>extensively drug resistant</p></def></def-item></def-list></glossary><sec id="S22" sec-type="data-availability"><title>Availability and requirements</title><p id="P39">Project name: GenoTyphi</p><p id="P40">Project home page: <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link></p><p id="P41">Operating system(s): Platform independent</p><p id="P42">Programming language: Python3 or higher</p><p id="P43">Other requirements: Mykrobe</p><p id="P44">License: GNU General Public License</p><p id="P45">Any restrictions to use by non-academics: None</p><p id="P46">Project name: Mykrobe</p><p id="P47">Project home page: <ext-link ext-link-type="uri" xlink:href="https://github.com/Mykrobe-tools/mykrobe">https://github.com/Mykrobe-tools/mykrobe</ext-link></p><p id="P48">Operating system(s): Platform independent</p><p id="P49">Programming language: Python3 or higher</p><p id="P50">Other requirements: anytree 2.8.0 or higher, Biopython 1.79 or higher, PyVCF3 1.0.3 or higher, requests 2.27.1 or higher, mongoengine 0.24.1 or higher, cython 0.29.28 or higher, numpy 1.22.0 or higher, pytest</p><p id="P51">License: MIT License</p><p id="P52">Any restrictions to use by non-academics: None.</p></sec><sec id="S23" sec-type="data-availability"><title>Availability of data and materials</title><p id="P53">All code and instructions for genotyping isolates with GenoTyphi using Mykrobe is available in the GitHub repository at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/genotyphi">https://github.com/typhoidgenomics/genotyphi</ext-link>. The version reported in this paper is v2.1 (DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.13859721">10.5281/zenodo.13859721</ext-link>)</p><p id="P54">The datasets and analysis code used in this article are available in a GitHub repository at <ext-link ext-link-type="uri" xlink:href="https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe">https://github.com/typhoidgenomics/TyphoidGenomicsConsortiumMykrobe</ext-link>.</p></sec><fn-group><title>Declarations</title><fn id="FN1"><p id="P55"><bold>Ethics approval and consent to participate</bold></p><p id="P56">Each contributing study or surveillance program obtained local ethical and governance approvals, as reported in the primary publication for each dataset. Inclusion of data that were not yet public domain by August 2021 was approved by the Observational / Interventions Research Ethics Committee of the London School of Hygiene and Tropical Medicine (ref#26408), on the basis of details provided on the local ethical approvals for sample and data collection (listed in Carey et al, 2023, <xref ref-type="supplementary-material" rid="SD1">Supplementary file 1</xref>).</p></fn><fn id="FN2" fn-type="conflict"><p id="P57"><bold>Consent for publication</bold></p><p id="P58">Not applicable</p></fn><fn id="FN3" fn-type="conflict"><p id="P59"><bold>Competing interests</bold></p><p id="P60">MML was a co-developer of a Trivalent Salmonella (Enteritidis/Typhimurium/Typhi Vi) conjugate vaccine with Bharat Biotech International and the Wellcome Trust. MML has also received payments from Pfizer for consultancy work. MML holds US patents for “Compositions and Methods for Producing Bacterial Conjugate Vaccines”. MML was a member of a NIH DSMB that oversaw US government-funded efficacy trials of COVID-19 vaccines. DSMB was disbanded after several vaccines were given Emergency Use Authorization. MML was a member of the Vaccines and Related Biological Products Advisory Committee of the FDA. IIB was a consultant for the Weapons Threat Reduction Program, Global Affairs Canada. AJP has been involved an Oxford University partnership with AZ for development of COVI19 vaccines. AJP has received payments for consultancy work from Shionogi. AJP is chair of DHSC’s Joint Committee on Vaccination and Immunisation, is a chair of WHOs Salmonella TAG, and was a member of WHOs SAGE. AJP received support from MRNA – Moderna. KLC has received payments from Pfizer for presentations and travel support from BD. INO has received payments from the Wellcome Trust for consultancy work and receives royalties for books or book chapters published via Springer, Cornell University Press, and Oxford University Press. INO has received travel support from BMGF, ESCMID, and the American ASM and has held leadership or advisory roles for Wellcome SEDRIC, the BMGF surveillance advisory group, the Thomas Bassir Biomedical Foundation, and International Centre for Antimicrobial Resistance Solutions (ICARS) Technical Advisory Forum. ZI has received travel support from ETH Zurich.</p></fn><fn id="FN4" fn-type="con"><p id="P61"><bold>Authors’ Contributions</bold></p><p id="P62">DJI, JH, ZAD and KEH – Conceptualization.</p><p id="P63">DJI, JK, ZAD and KEH – Data curation.</p><p id="P64">JH, MH, ZI, ZAD and KEH – Software</p><p id="P65">DJI, JH, RRW, ZAD and KEH – Methodology</p><p id="P66">DJI, JK, AOA, NA, SA, PMA, IIB, MC, MAC, JC, PDG, HI, JJ, AK, KHK, MM, SN, SO, INO, SIAR, AR, DR, VS, MJS, AMS, GTS, KT, RRW, ZAD and KEH - Formal analysis</p><p id="P67">DJI, JK, AOA, NA, SA, PMA, IIB, MC, MAC, JC, PDG, BPH, HI, JJ, LMJ, AK, KHK, JK, ML, MM, SN, SO, INO, PEO, SIAR, AR, DR, VS, MJS, AMS, GTS, KT, RRW, ZAD and KEH - Investigation, DJI and KEH - Visualization,</p><p id="P68">DJI, ZAD and KEH - Writing – original draft,</p><p id="P69">DJI, JK, ZI, MH, JHK, AOA, NA, SA, PMA, IIB, MEC, MAC, JC, PDG, BPH, HI, JJ, LMJ, AK, KHK, JK, ML, MM, SN, SO, INO, PEO, SIAR, AR, DR, VS, MJS, AMS, GTS, KT, RRW, ZAD and KEH - Writing – review and editing</p><p id="P70">All authors read and approved the final manuscript.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meiring</surname><given-names>JE</given-names></name><name><surname>Khanam</surname><given-names>F</given-names></name><name><surname>Basnyat</surname><given-names>B</given-names></name><name><surname>Charles</surname><given-names>RC</given-names></name><name><surname>Crump</surname><given-names>JA</given-names></name><name><surname>Debellut</surname><given-names>F</given-names></name><etal/></person-group><article-title>Typhoid fever</article-title><source>Nat Rev Dis Prim</source><year>2023</year><volume>9</volume><fpage>71</fpage><pub-id pub-id-type="pmid">38097589</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Collaborators G 2017 T and P</collab><name><surname>Stanaway</surname><given-names>JD</given-names></name><name><surname>Reiner</surname><given-names>RC</given-names></name><name><surname>Blacker</surname><given-names>BF</given-names></name><name><surname>Goldberg</surname><given-names>EM</given-names></name><name><surname>Khalil</surname><given-names>IA</given-names></name><etal/></person-group><article-title>The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017</article-title><source>Lancet Infect Dis</source><year>2019</year><volume>19</volume><fpage>369</fpage><lpage>81</lpage><pub-id pub-id-type="pmcid">PMC6437314</pub-id><pub-id pub-id-type="pmid">30792131</pub-id><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30685-6</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="book"><source>The WHO AWaRe (Access, Watch, Reserve) antibiotic book</source><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><year>2022</year><comment>Licence: CC BY-NC-SA 3.0 IGO</comment></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabarro</surname><given-names>LE</given-names></name><name><surname>McCann</surname><given-names>N</given-names></name><name><surname>Herdman</surname><given-names>MT</given-names></name><name><surname>Dugan</surname><given-names>C</given-names></name><name><surname>Ladhani</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>D</given-names></name><etal/></person-group><article-title>British infection association guidelines for the diagnosis and management of enteric fever in England</article-title><source>J Infect</source><year>2022</year><volume>84</volume><fpage>469</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">35038438</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2021 Forecasting Collaborators</collab><name><surname>Vollset</surname><given-names>SE</given-names></name><name><surname>Ababneh</surname><given-names>HS</given-names></name><name><surname>Abate</surname><given-names>YH</given-names></name><name><surname>Abbafati</surname><given-names>C</given-names></name><name><surname>Abbasgholizadeh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>2204</fpage><lpage>56</lpage><pub-id pub-id-type="pmcid">PMC11121021</pub-id><pub-id pub-id-type="pmid">38762325</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(24)00685-8</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>KE</given-names></name><name><surname>Tanmoy</surname><given-names>AM</given-names></name><name><surname>Pragasam</surname><given-names>AK</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Sajib</surname><given-names>MSI</given-names></name><name><surname>Mutreja</surname><given-names>A</given-names></name><etal/></person-group><article-title>The international and intercontinental spread and expansion of antimicrobial-resistant <italic>Salmonella</italic> Typhi: a genomic epidemiology study</article-title><source>Lancet Microbe</source><year>2022</year><volume>3</volume><fpage>e567</fpage><lpage>77</lpage><pub-id pub-id-type="pmcid">PMC9329132</pub-id><pub-id pub-id-type="pmid">35750070</pub-id><pub-id pub-id-type="doi">10.1016/S2666-5247(22)00093-3</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>MJ</given-names></name><name><surname>Birhane</surname><given-names>MG</given-names></name><name><surname>Dorough</surname><given-names>L</given-names></name><name><surname>Reynolds</surname><given-names>JL</given-names></name><name><surname>Caidi</surname><given-names>H</given-names></name><name><surname>Tagg</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Extensively Drug-Resistant Typhoid Fever in the United States</article-title><source>Open Forum Infect Dis</source><year>2021</year><volume>8</volume><elocation-id>ofab572</elocation-id><pub-id pub-id-type="pmcid">PMC8669042</pub-id><pub-id pub-id-type="pmid">34917695</pub-id><pub-id pub-id-type="doi">10.1093/ofid/ofab572</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>J</given-names></name><name><surname>Chaguza</surname><given-names>C</given-names></name><name><surname>Grubaugh</surname><given-names>ND</given-names></name><name><surname>Carey</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Assessing the global risk of typhoid outbreaks caused by extensively drug resistant <italic>Salmonella</italic> Typhi</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>6502</fpage><pub-id pub-id-type="pmcid">PMC10579367</pub-id><pub-id pub-id-type="pmid">37845201</pub-id><pub-id pub-id-type="doi">10.1038/s41467-023-42353-9</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posen</surname><given-names>HJ</given-names></name><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>Farrar</surname><given-names>DS</given-names></name><name><surname>Campigotto</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>T</given-names></name><name><surname>Barker</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions</article-title><source>J Travel Med</source><year>2022</year><volume>30</volume><elocation-id>taac086</elocation-id><pub-id pub-id-type="pmid">35904457</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lyu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Extensively Drug-Resistant (XDR) <italic>Salmonella</italic> Typhi Outbreak by Waterborne Infection — Beijing Municipality, China</article-title><source>China CDC Wkly</source><year>2022</year><volume>4</volume><fpage>254</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC9005487</pub-id><pub-id pub-id-type="pmid">35433085</pub-id><pub-id pub-id-type="doi">10.46234/ccdcw2022.062</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nizamuddin</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>EA</given-names></name><name><surname>Chattaway</surname><given-names>MA</given-names></name><name><surname>Godbole</surname><given-names>G</given-names></name></person-group><article-title>Case of Carbapenem-Resistant <italic>Salmonella</italic> Typhi Infection Pakistan, 2022</article-title><source>Emerg Infect Dis</source><year>2023</year><volume>29</volume><fpage>2395</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC10617351</pub-id><pub-id pub-id-type="pmid">37877663</pub-id><pub-id pub-id-type="doi">10.3201/eid2911.230499</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyson</surname><given-names>ZA</given-names></name><name><surname>Klemm</surname><given-names>EJ</given-names></name><name><surname>Palmer</surname><given-names>S</given-names></name><name><surname>Dougan</surname><given-names>G</given-names></name></person-group><article-title>Antibiotic Resistance and Typhoid</article-title><source>Clin Infect Dis</source><year>2019</year><volume>68</volume><fpage>S165</fpage><lpage>70</lpage><pub-id pub-id-type="pmcid">PMC6405283</pub-id><pub-id pub-id-type="pmid">30845331</pub-id><pub-id pub-id-type="doi">10.1093/cid/ciy1111</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argimon</surname><given-names>S</given-names></name><name><surname>Yeats</surname><given-names>CA</given-names></name><name><surname>Goater</surname><given-names>RJ</given-names></name><name><surname>Abudahab</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>B</given-names></name><name><surname>Underwood</surname><given-names>A</given-names></name><etal/></person-group><article-title>A global resource for genomic predictions of antimicrobial resistance and surveillance of <italic>Salmonella</italic> Typhi at pathogenwatch</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>2879</fpage><pub-id pub-id-type="pmcid">PMC8128892</pub-id><pub-id pub-id-type="pmid">34001879</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-23091-2</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>ME</given-names></name><name><surname>Dyson</surname><given-names>ZA</given-names></name><name><surname>Ingle</surname><given-names>DJ</given-names></name><name><surname>Amir</surname><given-names>A</given-names></name><name><surname>Aworh</surname><given-names>MK</given-names></name><name><surname>Chattaway</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 <italic>Salmonella</italic> Typhi genomes</article-title><source>eLife</source><year>2023</year><volume>12</volume><elocation-id>e85867</elocation-id><pub-id pub-id-type="pmcid">PMC10506625</pub-id><pub-id pub-id-type="pmid">37697804</pub-id><pub-id pub-id-type="doi">10.7554/eLife.85867</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>VK</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Pickard</surname><given-names>DJ</given-names></name><name><surname>Parkhill</surname><given-names>J</given-names></name><name><surname>Page</surname><given-names>AJ</given-names></name><name><surname>Feasey</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Phylogeographical analysis of the dominant multidrug-resistant H58 clade of <italic>Salmonella</italic> Typhi identifies inter- and intracontinental transmission events</article-title><source>Nat Genet</source><year>2015</year><volume>47</volume><fpage>632</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC4921243</pub-id><pub-id pub-id-type="pmid">25961941</pub-id><pub-id pub-id-type="doi">10.1038/ng.3281</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooda</surname><given-names>Y</given-names></name><name><surname>Sajib</surname><given-names>MSI</given-names></name><name><surname>Rahman</surname><given-names>H</given-names></name><name><surname>Luby</surname><given-names>SP</given-names></name><name><surname>Bondy-Denomy</surname><given-names>J</given-names></name><name><surname>Santosham</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular mechanism of azithromycin resistance among typhoidal <italic>Salmonella</italic> strains in Bangladesh identified through passive pediatric surveillance</article-title><source>Plos Neglect Trop D</source><year>2019</year><volume>13</volume><elocation-id>e0007868</elocation-id><pub-id pub-id-type="pmcid">PMC6881056</pub-id><pub-id pub-id-type="pmid">31730615</pub-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0007868</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>MR</given-names></name><name><surname>Doumith</surname><given-names>M</given-names></name><name><surname>Nascimento</surname><given-names>VD</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Ashton</surname><given-names>PM</given-names></name><name><surname>Jenkins</surname><given-names>C</given-names></name><etal/></person-group><article-title>Comparison of phenotypic and WGS-derived antimicrobial resistance profiles of <italic>Salmonella enterica</italic> serovars Typhi and Paratyphi</article-title><source>J Antimicrob Chemoth</source><year>2017</year><volume>73</volume><fpage>365</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">29216342</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>VK</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Connor</surname><given-names>TR</given-names></name><name><surname>Pickard</surname><given-names>D</given-names></name><name><surname>Page</surname><given-names>AJ</given-names></name><name><surname>Dave</surname><given-names>J</given-names></name><etal/></person-group><article-title>An extended genotyping framework for <italic>Salmonella enterica</italic> serovar Typhi, the cause of human typhoid</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><elocation-id>12827</elocation-id><pub-id pub-id-type="pmcid">PMC5059462</pub-id><pub-id pub-id-type="pmid">27703135</pub-id><pub-id pub-id-type="doi">10.1038/ncomms12827</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingle</surname><given-names>DJ</given-names></name><name><surname>Andersson</surname><given-names>P</given-names></name><name><surname>Valcanis</surname><given-names>M</given-names></name><name><surname>Wilmot</surname><given-names>M</given-names></name><name><surname>Easton</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>C</given-names></name><etal/></person-group><article-title>Genomic Epidemiology and Antimicrobial Resistance Mechanisms of Imported Typhoid in Australia</article-title><source>Antimicrob Agents Ch</source><year>2021</year><volume>65</volume><fpage>e01200</fpage><lpage>21</lpage><pub-id pub-id-type="pmcid">PMC8597785</pub-id><pub-id pub-id-type="pmid">34543095</pub-id><pub-id pub-id-type="doi">10.1128/AAC.01200-21</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikhimiukor</surname><given-names>OO</given-names></name><name><surname>Oaikhena</surname><given-names>AO</given-names></name><name><surname>Afolayan</surname><given-names>AO</given-names></name><name><surname>Fadeyi</surname><given-names>A</given-names></name><name><surname>Kehinde</surname><given-names>A</given-names></name><name><surname>Ogunleye</surname><given-names>VO</given-names></name><etal/></person-group><article-title>Genomic characterization of invasive typhoidal and non-typhoidal <italic>Salmonella</italic> in southwestern Nigeria</article-title><source>PLoS Neglected Trop Dis</source><year>2022</year><volume>16</volume><elocation-id>e0010716</elocation-id><pub-id pub-id-type="pmcid">PMC9455843</pub-id><pub-id pub-id-type="pmid">36026470</pub-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0010716</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sikorski</surname><given-names>MJ</given-names></name><name><surname>Hazen</surname><given-names>TH</given-names></name><name><surname>Desai</surname><given-names>SN</given-names></name><name><surname>Nimarota-Brown</surname><given-names>S</given-names></name><name><surname>Tupua</surname><given-names>S</given-names></name><name><surname>Sialeipata</surname><given-names>M</given-names></name><etal/></person-group><article-title>Persistence of Rare <italic>Salmonella</italic> Typhi Genotypes Susceptible to First-Line Antibiotics in the Remote Islands of Samoa</article-title><source>Mbio</source><year>2022</year><volume>13</volume><fpage>e01920</fpage><lpage>22</lpage><pub-id pub-id-type="pmcid">PMC9600463</pub-id><pub-id pub-id-type="pmid">36094088</pub-id><pub-id pub-id-type="doi">10.1128/mbio.01920-22</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyson</surname><given-names>ZA</given-names></name><name><surname>Holt</surname><given-names>KE</given-names></name></person-group><article-title>Five years of GenoTyphi: updates to the global <italic>Salmonella</italic> Typhi genotyping framework</article-title><source>J Infect Dis</source><year>2021</year><volume>224</volume><elocation-id>jiab414</elocation-id><pub-id pub-id-type="pmcid">PMC8687072</pub-id><pub-id pub-id-type="pmid">34453548</pub-id><pub-id pub-id-type="doi">10.1093/infdis/jiab414</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britto</surname><given-names>CD</given-names></name><name><surname>Dyson</surname><given-names>ZA</given-names></name><name><surname>Duchene</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>MJ</given-names></name><name><surname>Gurung</surname><given-names>M</given-names></name><name><surname>Kelly</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Laboratory and molecular surveillance of paediatric typhoidal <italic>Salmonella</italic> in Nepal: Antimicrobial resistance and implications for vaccine policy</article-title><source>Plos Neglect Trop D</source><year>2018</year><volume>12</volume><elocation-id>e0006408</elocation-id><pub-id pub-id-type="pmcid">PMC5933809</pub-id><pub-id pub-id-type="pmid">29684021</pub-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006408</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>SIA</given-names></name><name><surname>Dyson</surname><given-names>ZA</given-names></name><name><surname>Klemm</surname><given-names>EJ</given-names></name><name><surname>Khanam</surname><given-names>F</given-names></name><name><surname>Holt</surname><given-names>KE</given-names></name><name><surname>Chowdhury</surname><given-names>EK</given-names></name><etal/></person-group><article-title>Population structure and antimicrobial resistance patterns of <italic>Salmonella</italic> Typhi isolates in urban Dhaka, Bangladesh from 2004 to 2016</article-title><source>Plos Neglect Trop D</source><year>2020</year><volume>14</volume><elocation-id>e0008036</elocation-id><pub-id pub-id-type="pmcid">PMC7064254</pub-id><pub-id pub-id-type="pmid">32106221</pub-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0008036</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanmoy</surname><given-names>AM</given-names></name><name><surname>Westeel</surname><given-names>E</given-names></name><name><surname>Bruyne</surname><given-names>KD</given-names></name><name><surname>Goris</surname><given-names>J</given-names></name><name><surname>Rajoharison</surname><given-names>A</given-names></name><name><surname>Sajib</surname><given-names>MSI</given-names></name><etal/></person-group><article-title><italic>Salmonella enterica</italic> Serovar Typhi in Bangladesh: Exploration of Genomic Diversity and Antimicrobial Resistance</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e02112</fpage><lpage>18</lpage><pub-id pub-id-type="pmcid">PMC6234861</pub-id><pub-id pub-id-type="pmid">30425150</pub-id><pub-id pub-id-type="doi">10.1128/mBio.02112-18</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemm</surname><given-names>EJ</given-names></name><name><surname>Shakoor</surname><given-names>S</given-names></name><name><surname>Page</surname><given-names>AJ</given-names></name><name><surname>Qamar</surname><given-names>FN</given-names></name><name><surname>Judge</surname><given-names>K</given-names></name><name><surname>Saeed</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Emergence of an Extensively Drug-Resistant <italic>Salmonella enterica</italic> Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e00105</fpage><lpage>18</lpage><pub-id pub-id-type="pmcid">PMC5821095</pub-id><pub-id pub-id-type="pmid">29463654</pub-id><pub-id pub-id-type="doi">10.1128/mBio.00105-18</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kariuki</surname><given-names>S</given-names></name><name><surname>Dyson</surname><given-names>ZA</given-names></name><name><surname>Mbae</surname><given-names>C</given-names></name><name><surname>Ngetich</surname><given-names>R</given-names></name><name><surname>Kavai</surname><given-names>SM</given-names></name><name><surname>Wairimu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multiple introductions of multidrug-resistant typhoid associated with acute infection and asymptomatic carriage, Kenya</article-title><source>eLife</source><year>2021</year><volume>10</volume><elocation-id>e67852</elocation-id><pub-id pub-id-type="pmcid">PMC8494480</pub-id><pub-id pub-id-type="pmid">34515028</pub-id><pub-id pub-id-type="doi">10.7554/eLife.67852</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ingle</surname><given-names>DJ</given-names></name><name><surname>Hawkey</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>M</given-names></name><name><surname>Dyson</surname><given-names>ZA</given-names></name><name><surname>Holt</surname><given-names>KE</given-names></name></person-group><source>Technical Report: GenoTyphi Implementation in Mykrobe</source><publisher-name>Zenodo</publisher-name><year>2022</year><pub-id pub-id-type="doi">10.5281/zenodo.7407984</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkhill</surname><given-names>J</given-names></name><name><surname>Dougan</surname><given-names>G</given-names></name><name><surname>James</surname><given-names>KD</given-names></name><name><surname>Thomson</surname><given-names>NR</given-names></name><name><surname>Pickard</surname><given-names>D</given-names></name><name><surname>Wain</surname><given-names>J</given-names></name><etal/></person-group><article-title>Complete genome sequence of a multiple drug resistant <italic>Salmonella enterica</italic> serovar Typhi CT18</article-title><source>Nature</source><year>2001</year><volume>413</volume><fpage>848</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11677608</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labbe</surname><given-names>G</given-names></name><name><surname>Kruczkiewicz</surname><given-names>P</given-names></name><name><surname>Robertson</surname><given-names>J</given-names></name><name><surname>Mabon</surname><given-names>P</given-names></name><name><surname>Schonfeld</surname><given-names>J</given-names></name><name><surname>Kein</surname><given-names>D</given-names></name><etal/></person-group><article-title>Rapid and accurate SNP genotyping of clonal bacterial pathogens with BioHansel</article-title><source>Microb Genom</source><year>2021</year><volume>7</volume><elocation-id>000651</elocation-id><pub-id pub-id-type="pmcid">PMC8715432</pub-id><pub-id pub-id-type="pmid">34554082</pub-id><pub-id pub-id-type="doi">10.1099/mgen.0.000651</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>M</given-names></name><name><surname>Bradley</surname><given-names>P</given-names></name><name><surname>Lapierre</surname><given-names>SG</given-names></name><name><surname>Heys</surname><given-names>S</given-names></name><name><surname>Thomsit</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Antibiotic resistance prediction for <italic>Mycobacterium tuberculosis</italic> from genome sequence data with Mykrobe</article-title><source>Wellcome Open Res</source><year>2019</year><volume>4</volume><fpage>191</fpage><pub-id pub-id-type="pmcid">PMC7004237</pub-id><pub-id pub-id-type="pmid">32055708</pub-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.15603.1</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Holt</surname><given-names>K</given-names></name><name><surname>Whitehead</surname><given-names>S</given-names></name><name><surname>Goodhead</surname><given-names>I</given-names></name><name><surname>Perkins</surname><given-names>T</given-names></name><name><surname>Stocker</surname><given-names>B</given-names></name><etal/></person-group><article-title>A linear plasmid truncation induces unidirectional flagellar phase change in H:z66 positive <italic>Salmonella</italic> Typhi</article-title><source>Mol Microbiol</source><year>2007</year><volume>66</volume><fpage>1207</fpage><lpage>18</lpage><pub-id pub-id-type="pmcid">PMC2652032</pub-id><pub-id pub-id-type="pmid">17976161</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05995.x</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>KE</given-names></name><name><surname>Phan</surname><given-names>MD</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Duy</surname><given-names>PT</given-names></name><name><surname>Nga</surname><given-names>TVT</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><etal/></person-group><article-title>Emergence of a Globally Dominant IncHI1 Plasmid Type Associated with Multiple Drug Resistant Typhoid</article-title><source>Plos Neglect Trop D</source><year>2011</year><volume>5</volume><elocation-id>e1245</elocation-id><pub-id pub-id-type="pmcid">PMC3139670</pub-id><pub-id pub-id-type="pmid">21811646</pub-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001245</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>NC</given-names></name><name><surname>Walker</surname><given-names>TM</given-names></name><name><surname>Dunn</surname><given-names>L</given-names></name><name><surname>Heys</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and <italic>Mycobacterium tuberculosis</italic></article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><elocation-id>10063</elocation-id><pub-id pub-id-type="pmcid">PMC4703848</pub-id><pub-id pub-id-type="pmid">26686880</pub-id><pub-id pub-id-type="doi">10.1038/ncomms10063</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>TM</given-names></name><name><surname>Miotto</surname><given-names>P</given-names></name><name><surname>Koser</surname><given-names>CU</given-names></name><name><surname>Fowler</surname><given-names>PW</given-names></name><name><surname>Knaggs</surname><given-names>J</given-names></name><name><surname>Iqbal</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The 2021 WHO catalogue of <italic>Mycobacterium tuberculosis</italic> complex mutations associated with drug resistance: a genotypic analysis</article-title><source>Lancet Microbe</source><year>2022</year><volume>3</volume><fpage>e265</fpage><lpage>73</lpage><pub-id pub-id-type="pmcid">PMC7612554</pub-id><pub-id pub-id-type="pmid">35373160</pub-id><pub-id pub-id-type="doi">10.1016/S2666-5247(21)00301-3</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>MB</given-names></name><name><surname>Coin</surname><given-names>LJM</given-names></name></person-group><article-title>Assessment of the 2021 WHO <italic>Mycobacterium tuberculosis</italic> drug resistance mutation catalogue on an independent dataset</article-title><source>Lancet Microbe</source><year>2022</year><volume>3</volume><fpage>e645</fpage><pub-id pub-id-type="pmid">35659881</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkey</surname><given-names>J</given-names></name><name><surname>Paranagama</surname><given-names>K</given-names></name><name><surname>Baker</surname><given-names>KS</given-names></name><name><surname>Bengtsson</surname><given-names>RJ</given-names></name><name><surname>Weill</surname><given-names>F-X</given-names></name><name><surname>Thomson</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Global population structure and genotyping framework for genomic surveillance of the major dysentery pathogen, <italic>Shigella sonnei</italic></article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>2684</fpage><pub-id pub-id-type="pmcid">PMC8113504</pub-id><pub-id pub-id-type="pmid">33976138</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-22700-4</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanh</surname><given-names>DP</given-names></name><name><surname>Karkey</surname><given-names>A</given-names></name><name><surname>Dongol</surname><given-names>S</given-names></name><name><surname>Thi</surname><given-names>NH</given-names></name><name><surname>Thompson</surname><given-names>CN</given-names></name><name><surname>Rabaa</surname><given-names>MA</given-names></name><etal/></person-group><article-title>A novel ciprofloxacin-resistant subclade of H58 <italic>Salmonella</italic> Typhi is associated with fluoroquinolone treatment failure</article-title><source>Elife</source><year>2016</year><volume>5</volume><elocation-id>e14003</elocation-id><pub-id pub-id-type="pmcid">PMC4805543</pub-id><pub-id pub-id-type="pmid">26974227</pub-id><pub-id pub-id-type="doi">10.7554/eLife.14003</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crump</surname><given-names>JA</given-names></name><name><surname>Kretsinger</surname><given-names>K</given-names></name><name><surname>Gay</surname><given-names>K</given-names></name><name><surname>Hoekstra</surname><given-names>RM</given-names></name><name><surname>Vugia</surname><given-names>DJ</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical Response and Outcome of Infection with <italic>Salmonella enterica</italic> Serotype Typhi with Decreased Susceptibility to Fluoroquinolones: a United States FoodNet Multicenter Retrospective Cohort Study</article-title><source>Antimicrob Agents Chemother</source><year>2008</year><volume>52</volume><fpage>1278</fpage><lpage>84</lpage><pub-id pub-id-type="pmcid">PMC2292528</pub-id><pub-id pub-id-type="pmid">18212096</pub-id><pub-id pub-id-type="doi">10.1128/AAC.01509-07</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bankevich</surname><given-names>A</given-names></name><name><surname>Nurk</surname><given-names>S</given-names></name><name><surname>Antipov</surname><given-names>D</given-names></name><name><surname>Gurevich</surname><given-names>AA</given-names></name><name><surname>Dvorkin</surname><given-names>M</given-names></name><name><surname>Kulikov</surname><given-names>AS</given-names></name><etal/></person-group><article-title>SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing</article-title><source>J Comput Biol</source><year>2012</year><volume>19</volume><fpage>455</fpage><lpage>77</lpage><pub-id pub-id-type="pmcid">PMC3342519</pub-id><pub-id pub-id-type="pmid">22506599</pub-id><pub-id pub-id-type="doi">10.1089/cmb.2012.0021</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prjibelski</surname><given-names>A</given-names></name><name><surname>Antipov</surname><given-names>D</given-names></name><name><surname>Meleshko</surname><given-names>D</given-names></name><name><surname>Lapidus</surname><given-names>A</given-names></name><name><surname>Korobeynikov</surname><given-names>A</given-names></name></person-group><article-title>Using SPAdes De Novo Assembler</article-title><source>Curr Protoc Bioinform</source><year>2020</year><volume>70</volume><fpage>e102</fpage><pub-id pub-id-type="pmid">32559359</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><name><surname>Averick</surname><given-names>M</given-names></name><name><surname>Bryan</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>McGowan</surname><given-names>L</given-names></name><name><surname>Francois</surname><given-names>R</given-names></name><etal/></person-group><article-title>Welcome to the Tidyverse</article-title><source>J Open Source Softw</source><year>2019</year><volume>4</volume><fpage>1686</fpage><pub-id pub-id-type="doi">10.21105/joss.01686</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chattaway</surname><given-names>MA</given-names></name><name><surname>Gentle</surname><given-names>A</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Tingley</surname><given-names>L</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Mohamed</surname><given-names>I</given-names></name><etal/></person-group><article-title>Phylogenomics and antimicrobial resistance of <italic>Salmonella</italic> Typhi and Paratyphi A, B and C in England, 2016-2019</article-title><source>Microb Genom</source><year>2021</year><volume>7</volume><pub-id pub-id-type="pmcid">PMC8549371</pub-id><pub-id pub-id-type="pmid">34370659</pub-id><pub-id pub-id-type="doi">10.1099/mgen.0.000633</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="book"><collab>CDC</collab><source>National Antimicrobial Resistance Monitoring System (NARMS) Now: Human Data</source><publisher-loc>Atlanta, Georgia</publisher-loc><publisher-name>U.S. Department of Health and Human Services, CDC</publisher-name><comment>[Internet]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/narmsnow">https://www.cdc.gov/narmsnow</ext-link></comment></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reller</surname><given-names>LB</given-names></name><name><surname>Weinstein</surname><given-names>M</given-names></name><name><surname>Jorgensen</surname><given-names>JH</given-names></name><name><surname>Ferraro</surname><given-names>MJ</given-names></name></person-group><article-title>Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices</article-title><source>Clin Infect Dis</source><year>2009</year><volume>49</volume><fpage>1749</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">19857164</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="web"><collab>U.S Food and Drug Administration</collab><source>Antimicrobial Susceptibility Test (AST) Systems - Class II Special Controls Guidance for Industry and FDA</source><comment>[Internet] Available <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/88069/download">https://www.fda.gov/media/88069/download</ext-link></comment></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcock</surname><given-names>BP</given-names></name><name><surname>Huynh</surname><given-names>W</given-names></name><name><surname>Chalil</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>KW</given-names></name><name><surname>Raphenya</surname><given-names>AR</given-names></name><name><surname>Wlodarski</surname><given-names>MA</given-names></name><etal/></person-group><article-title>CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>51</volume><fpage>D690</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC9825576</pub-id><pub-id pub-id-type="pmid">36263822</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkac920</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolmogorov</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Pevzner</surname><given-names>PA</given-names></name></person-group><article-title>Assembly of long, error-prone reads using repeat graphs</article-title><source>Nat Biotechnol</source><year>2019</year><volume>37</volume><fpage>540</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">30936562</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greig</surname><given-names>DR</given-names></name><name><surname>Bird</surname><given-names>MT</given-names></name><name><surname>Chattaway</surname><given-names>MA</given-names></name><name><surname>Langridge</surname><given-names>GC</given-names></name><name><surname>Waters</surname><given-names>EV</given-names></name><name><surname>Ribeca</surname><given-names>P</given-names></name><etal/></person-group><article-title>Characterization of a P1-bacteriophage-like plasmid (phage-plasmid) harbouring bla CTX-M-15 in <italic>Salmonella enterica</italic> serovar Typhi</article-title><source>Microb Genom</source><year>2022</year><volume>8</volume><elocation-id>mgen000913</elocation-id><pub-id pub-id-type="pmcid">PMC9837566</pub-id><pub-id pub-id-type="pmid">36748517</pub-id><pub-id pub-id-type="doi">10.1099/mgen.0.000913</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Barker</surname><given-names>CR</given-names></name><name><surname>Bird</surname><given-names>M</given-names></name><name><surname>Greig</surname><given-names>DR</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name><name><surname>Painset</surname><given-names>A</given-names></name><etal/></person-group><article-title>Presence of phage-plasmids in multiple serovars of <italic>Salmonella enterica</italic></article-title><source>Microb Genom</source><year>2024</year><volume>10</volume><elocation-id>001247</elocation-id><pub-id pub-id-type="pmcid">PMC11165635</pub-id><pub-id pub-id-type="pmid">38717818</pub-id><pub-id pub-id-type="doi">10.1099/mgen.0.001247</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldblatt</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Yusuf</surname><given-names>M</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Godbole</surname><given-names>G</given-names></name><name><surname>Morris-Jones</surname><given-names>S</given-names></name></person-group><article-title>Azithromycin susceptibility testing for <italic>Salmonella enterica</italic> isolates: discordances in results using MIC gradient strips</article-title><source>J Antimicrob Chemother</source><year>2020</year><volume>75</volume><fpage>1820</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">32221592</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabeen</surname><given-names>K</given-names></name><name><surname>Saleem</surname><given-names>S</given-names></name><name><surname>Nizamuddin</surname><given-names>S</given-names></name><name><surname>Arshad</surname><given-names>F</given-names></name><name><surname>Jahan</surname><given-names>S</given-names></name><name><surname>Hasnain</surname><given-names>F</given-names></name><etal/></person-group><article-title>Reporting of Azithromycin Activity against Clinical Isolates of Extensively Drug-Resistant <italic>Salmonella enterica</italic> Serovar Typhi</article-title><source>Am J Trop Med Hyg</source><year>2023</year><volume>108</volume><fpage>942</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC10160884</pub-id><pub-id pub-id-type="pmid">36940665</pub-id><pub-id pub-id-type="doi">10.4269/ajtmh.22-0557</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellington</surname><given-names>MJ</given-names></name><name><surname>Ekelund</surname><given-names>O</given-names></name><name><surname>Aarestrup</surname><given-names>FM</given-names></name><name><surname>Canton</surname><given-names>R</given-names></name><name><surname>Doumith</surname><given-names>M</given-names></name><name><surname>Giske</surname><given-names>C</given-names></name><etal/></person-group><article-title>The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee</article-title><source>Clin Microbiol Infect</source><year>2017</year><volume>23</volume><fpage>2</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">27890457</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>R</given-names></name></person-group><source>Yet another ONT accuracy test: Dorado v0.5.0 2023</source><publisher-name>Zenodo</publisher-name><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/records/10397818">https://zenodo.org/records/10397818</ext-link></comment></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Typhi Mykrobe functionality</title><p>A) A schematic overview of the Typhi Mykrobe pipeline. B) Table of epidemiologically important AMR determinants targeted for detection/typing by Typhi Mykrobe, grouped by drug. C) Table of epidemiologically important plasmid replicons targeted for detection by Typhi Mykrobe.</p></caption><graphic xlink:href="EMS199185-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Validation of Typhi Mykrobe AMR predictions vs AMR phenotypes</title><p>Summary of Typhi Mykrobe’s genotype-based clinical resistance categorisations compared with susceptibility phenotypes, for 4,018 isolates with publicly available matched genome and phenotype data. Comparisons are summarised as categorical agreement, and calculated separately for the three different source datasets, which used different phenotyping methods and interpretive standards (US CDC: MIC, CLSI; UKHSA: MIC, EUCAST; SEAP: disk diffusion, EUCAST; see Methods). Major errors were defined as susceptible isolates with AMR determinants detected (reported as R by Mykrobe). Very major errors were defined as resistant isolates with no AMR determinants detected (reported as S by Mykrobe). Error bars are shown that represent 95% confidence interval of proportion. Note UKHSA tested amoxicillin rather than ampicillin, the result is reported in the ampicillin row.</p></caption><graphic xlink:href="EMS199185-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Typhi Mykrobe genotypes vs minimum inhibitory concentration from two reference laboratories, for ciprofloxacin.</title><p><bold>a)</bold> UKHSA dataset, using EUCAST. <bold>b)</bold> US CDC dataset, using CLSI. Each column represents the set of isolates in which Typhi Mykrobe identified a unique combination of genetic determinants, indicated in the panel at the bottom. For each column, the violin plots show the distribution of ciprofloxacin MIC values, and stacked barplots show the proportion of genomes called as S, I, or R (coloured as per inset legend, and labelled with counts). The solid horizontal lines on the violin plots mark the R breakpoint, the dashed line marks the CLSI I breakpoint used for the US CDC dataset.</p></caption><graphic xlink:href="EMS199185-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Typhi Mykrobe genotypes vs disk diffusion data from the SEAP study, for three drug classes</title><p>Data for three drugs are shown in panels <bold>a)</bold> Azithromycin, <bold>b)</bold> Ceftriaxone, and <bold>c)</bold> Ciprofloxacin. Each column represents the set of isolates in which Typhi Mykrobe identified a unique combination of genetic determinants, indicated in the panel at the bottom. For each column, the violin plots show the distribution of disk diffusion values for azithromycin, ceftriaxonne or ciprofloxacin. The stacked barplots show the proportion of genomes called as S, I, or R (coloured as per inset legend, and labelled with counts). The solid horizontal lines on the violin plots mark the R EUCAST breakpoint used for the SEAP disk diffusion data. The dashed line marks the EUCAST breakpoint for I.</p></caption><graphic xlink:href="EMS199185-f004"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Validation of genotype calls</title><p>Summary of Typhi Mykrobe genotype calls (GenoTyphi scheme) for 12,839 Illumina readsets, compared with mapping-based genotype calls.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top">Typhi Mykrobe vs mapping-based genotype calls</th><th align="left" valign="top">Genomes (N)</th></tr></thead><tbody><tr><td align="left" valign="top"><italic>invA</italic>-negative, thus designated non-Typhi and not genotyped by Mykrobe</td><td align="left" valign="top">5</td></tr><tr><td align="left" valign="top">Single genotype, exact match</td><td align="left" valign="top">12,807</td></tr><tr><td align="left" valign="top">Two genotypes, exact match (reported differently)</td><td align="left" valign="top">17</td></tr><tr><td align="left" valign="top">Genotype 3.5.3, mismatch (reported incorrectly by mapping pipeline as 3.5.4 due to breaking hierarchy assumption)</td><td align="left" valign="top">8</td></tr><tr><td align="left" valign="top">Discordant result (low support reported by mapping-based pipeline, phylogenetic tree supports Mykrobe call)</td><td align="left" valign="top">2</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Validation of AMR genotyping (vs assembly based)</title><p>Comparison of AMR genotyping by Typhi Mykrobe (kmer-based analysis of reads) vs Pathogenwatch (based on nucleotide blast search of assemblies), for n=11,992 isolates. Complete details of the call comparisons are given in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>. Categorical agreement at drug level is calculated based on agreement of the binary S/R categorisation of the 11,992 isolates by each method (i.e. ‘Concordant’ means Typhi Mykrobe and Typhi Pathogenwatch made the same call of S or R based on absence or presence, respectively, of known genetic determinants; ‘Discordant’ means one method identified determinants and called R, while the other did not and called S). *For ciprofloxacin, both tools categorise as S/I/R as defined in Methods, and categorical agreement was calculated across these three categories. **Results for <italic>dfrA</italic> genes are summarised together, and as some genomes have multiple <italic>dfrA</italic> alleles the total observations is greater than the number of isolates (see details in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>).</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top">Drug</th><th align="left" valign="top">Agreement (drug level)</th><th align="left" valign="top">Genetic marker</th><th align="left" valign="top">Concordant</th><th align="left" valign="top">Discordant</th><th align="left" valign="top">Agreement (marker level)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2"><bold>Ampicillin</bold></td><td align="left" valign="top" rowspan="2">99.72%</td><td align="left" valign="top"><italic>bla</italic>TEM-1</td><td align="left" valign="top">11,958</td><td align="left" valign="top">34</td><td align="left" valign="top">99.72%</td></tr><tr><td align="left" valign="top"><italic>bla</italic>OXA-7</td><td align="left" valign="top">11,991</td><td align="left" valign="top">1</td><td align="left" valign="top">99.99%</td></tr><tr><td align="left" valign="top" rowspan="2"><bold>Azithromycin</bold></td><td align="left" valign="top" rowspan="2">99.98%</td><td align="left" valign="top"><italic>acrB</italic>_717</td><td align="left" valign="top">11,991</td><td align="left" valign="top">1</td><td align="left" valign="top">99.99%</td></tr><tr><td align="left" valign="top"><italic>mphA</italic></td><td align="left" valign="top">11,992</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top" rowspan="4"><bold>Ceftriaxone</bold></td><td align="left" valign="top" rowspan="4">99.97%</td><td align="left" valign="top"><italic>bla</italic>CTX-M</td><td align="left" valign="top">11,990</td><td align="left" valign="top">3</td><td align="left" valign="top">99.97%</td></tr><tr><td align="left" valign="top"><italic>bla</italic>SHV-12</td><td align="left" valign="top">11,991</td><td align="left" valign="top">1</td><td align="left" valign="top">99.99%</td></tr><tr><td align="left" valign="top"><italic>bla</italic>OXA-134</td><td align="left" valign="top">11,992</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top"><italic>ampC</italic></td><td align="left" valign="top">11,992</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top" rowspan="2"><bold>Chloramphenicol</bold></td><td align="left" valign="top" rowspan="2">99.89%</td><td align="left" valign="top"><italic>catAI</italic></td><td align="left" valign="top">11,979</td><td align="left" valign="top">13</td><td align="left" valign="top">99.89%</td></tr><tr><td align="left" valign="top"><italic>cmlAI</italic></td><td align="left" valign="top">11,992</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top" rowspan="8"><bold>Ciprofloxacin*</bold></td><td align="left" valign="top" rowspan="8">99.72%</td><td align="left" valign="top"><italic>qnrB</italic></td><td align="left" valign="top">11,979</td><td align="left" valign="top">13</td><td align="left" valign="top">99.89%</td></tr><tr><td align="left" valign="top"><italic>qnrD</italic></td><td align="left" valign="top">11,992</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top"><italic>qnrS</italic></td><td align="left" valign="top">11,987</td><td align="left" valign="top">5</td><td align="left" valign="top">99.96%</td></tr><tr><td align="left" valign="top"><italic>gyrA</italic>_83</td><td align="left" valign="top">11,986</td><td align="left" valign="top">6</td><td align="left" valign="top">99.95%</td></tr><tr><td align="left" valign="top"><italic>gyrA</italic>_87</td><td align="left" valign="top">11,986</td><td align="left" valign="top">10</td><td align="left" valign="top">99.92%</td></tr><tr><td align="left" valign="top"><italic>gyrB</italic>_464</td><td align="left" valign="top">11,493</td><td align="left" valign="top">8</td><td align="left" valign="top">99.93%</td></tr><tr><td align="left" valign="top"><italic>parC</italic>_80</td><td align="left" valign="top">11,976</td><td align="left" valign="top">17</td><td align="left" valign="top">99.86%</td></tr><tr><td align="left" valign="top"><italic>parC</italic>_84</td><td align="left" valign="top">11,992</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top" rowspan="2"><bold>Sulfonamides</bold></td><td align="left" valign="top" rowspan="2">99.81%</td><td align="left" valign="top"><italic>sull</italic></td><td align="left" valign="top">11,971</td><td align="left" valign="top">21</td><td align="left" valign="top">99.82%</td></tr><tr><td align="left" valign="top"><italic>sul2</italic></td><td align="left" valign="top">11,819</td><td align="left" valign="top">173</td><td align="left" valign="top">98.56%</td></tr><tr><td align="left" valign="top"><bold>Trimethoprim</bold></td><td align="left" valign="top">99.83%</td><td align="left" valign="top"><italic>dfrA</italic> genes**</td><td align="left" valign="top">12,049</td><td align="left" valign="top">22</td><td align="left" valign="top">99.82%</td></tr><tr><td align="left" valign="top" rowspan="4"><bold>Tetracycline</bold></td><td align="left" valign="top" rowspan="4">99.85%</td><td align="left" valign="top"><italic>tetA(A)</italic></td><td align="left" valign="top">11,986</td><td align="left" valign="top">6</td><td align="left" valign="top">99.95%</td></tr><tr><td align="left" valign="top"><italic>tetA(B)</italic></td><td align="left" valign="top">11,980</td><td align="left" valign="top">12</td><td align="left" valign="top">99.90%</td></tr><tr><td align="left" valign="top"><italic>tetA(C)</italic></td><td align="left" valign="top">11,970</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top"><italic>tetA(D)</italic></td><td align="left" valign="top">11,970</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top">-</td><td align="left" valign="top">-</td><td align="left" valign="top"><bold>Total</bold></td><td align="left" valign="top"><bold>299,004</bold></td><td align="left" valign="top"><bold>346</bold></td><td align="left" valign="top"><bold>99.88%</bold></td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3</label><caption><title>Validation of plasmid replicon detection (vs assembly based).</title><p>Comparison of plasmid replicon markers identified in the genomes by Typhi Mykrobe (kmer-based analysis of reads) vs Pathogenwatch (PW, based on nucleotide blast search of assemblies), for n=11,992 isolates.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top">Plasmid replicon marker</th><th align="left" valign="top">Both</th><th align="left" valign="top">Mykrobe only</th><th align="left" valign="top">PW only</th><th align="left" valign="top">Agreement</th></tr></thead><tbody><tr><td align="left" valign="top">IncFIAHI1</td><td align="left" valign="top">251</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">100%</td></tr><tr><td align="left" valign="top">IncFIB(K)</td><td align="left" valign="top">175</td><td align="left" valign="top">0</td><td align="left" valign="top">1</td><td align="left" valign="top">99.99%</td></tr><tr><td align="left" valign="top">IncFIB(pHCM2)</td><td align="left" valign="top">1406</td><td align="left" valign="top">26</td><td align="left" valign="top">5</td><td align="left" valign="top">99.74%</td></tr><tr><td align="left" valign="top">IncHI1A</td><td align="left" valign="top">872</td><td align="left" valign="top">9</td><td align="left" valign="top">3</td><td align="left" valign="top">99.90%</td></tr><tr><td align="left" valign="top">IncHI1B</td><td align="left" valign="top">874</td><td align="left" valign="top">7</td><td align="left" valign="top">1</td><td align="left" valign="top">99.93%</td></tr><tr><td align="left" valign="top">IncHI2A</td><td align="left" valign="top">3</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top">IncI1</td><td align="left" valign="top">5</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top">IncL/M</td><td align="left" valign="top">1</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top">IncN</td><td align="left" valign="top">100</td><td align="left" valign="top">2</td><td align="left" valign="top">0</td><td align="left" valign="top">99.98%</td></tr><tr><td align="left" valign="top">IncX1</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">IncX3</td><td align="left" valign="top">21</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top">IncY</td><td align="left" valign="top">666</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">100.00%</td></tr><tr><td align="left" valign="top">p0111</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr></tbody></table></table-wrap></floats-group></article>